1
|
Zerdazi EH, Curis E, Karsinti E, Icick R, Fortias M, Batel P, Cottencin O, Orizet C, Gay A, Coeuru P, Deschenau A, Lack P, Moisan D, Pelissier-Alicot AL, Plat A, Trabut JB, Kousignian I, Boumendil L, Vicaut E, Prince N, Laplanche JL, Bellivier F, Lépine JP, Marie-Claire C, Brousse G, Vorspan F, Bloch V. Occurrence and severity of cocaine-induced hallucinations: Two distinct phenotypes with shared clinical factors but specific genetic risk factors. Drug Alcohol Depend 2022; 232:109270. [PMID: 35124387 DOI: 10.1016/j.drugalcdep.2022.109270] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 01/03/2022] [Accepted: 01/03/2022] [Indexed: 11/15/2022]
Abstract
UNLABELLED Cocaine-induced transient hallucinations (CIH) are a frequent complication following cocaine intake that is associated with addiction severity. METHODS Two hundred and forty-two non-psychotic and Caucasian lifetime cocaine users were included in a French multicentric study. Clinical variables and dopamine pathway genotype data were extracted and tested with CIH scores using a zero-inflated binomial model, which allows for the exploration of factors associated with occurrence and severity separately. RESULTS Cocaine dependence (poccurrence= 6.18 × 10-5, pseverity= 9.25 × 10-8), number of cocaine dependence DSM IV-Tr criteria (poccurrence= 1.22 × 10-7, pseverity= 5.09 × 10-6), and frequency of intake during the worst period of misuse (poccurrence= 8.51 × 10-04, pseverity= 0.04) were associated with greater occurrence and higher severity of CIH. The genetic associations did not yield significant results after correction for multiple tests. However, some nominal associations of SNPs mapped to the VMAT2, DBH, DRD1, and DRD2 genes were significant. In the multivariate model, the significant variables were the number of cocaine dependence criteria, lifetime alcohol dependence, and the nominally associated SNPs. CONCLUSION Our study shows that CIH occurrence and severity are two distinct phenotypes, with shared clinical risk factors; however, they likely do not share the same genetic background.
Collapse
Affiliation(s)
- El-Hadi Zerdazi
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, Hôpitaux Universitaires Henri Mondor, DMU IMPACT, Hôpital Emile ROUX, Service d'addictologie, Limeil Brévannes 94450, France.
| | - Emmanuel Curis
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; EA 7537 BioSTM, Faculté de Pharmacie, Université Paris Descartes, USPC, Paris 75006, France
| | - Emily Karsinti
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France; Université Paris Nanterre, Laboratoire Clipsyd, Nanterre 92000, France
| | - Romain Icick
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France
| | - Maeva Fortias
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France
| | - Philippe Batel
- Centre Hospitalier Camille Claudel, Service d'Addictologie de la Charente, La Couronne 16400, France
| | - Olivier Cottencin
- University of Lille, Inserm U-1172, CHU Lille, Department of Psychiatry and Addiction Medicine, Lille 59000, France
| | - Cyrille Orizet
- APHP, GHU Centre-Université de Paris, Hôpital Européen Georges Pompidou, CSAPA Monte-Cristo, Paris 75015, France
| | - Aurélia Gay
- CHU Saint-Etienne, Service d'Addictologie, Saint-Etienne 42000, France
| | | | - Alice Deschenau
- Hôpital Paul Guiraud, CSAPA Clinique Liberté, Ivry-sur-Seine 94200, France
| | - Philippe Lack
- Hôpital de la Croix Rousse, CSAPA, Lyon 69004, France
| | - Delphine Moisan
- APHP, GHU Nord-Université de Paris, Hôpital Beaujon, UTAMA, Clichy 92110, France
| | - Anne-Laure Pelissier-Alicot
- APHM, CHU La Timone, Service de Médecine légale, Aix-Marseille Université, Faculté de Médecine, Marseille 13385, France
| | - Arnaud Plat
- APHP, GHU Nord-Université de Paris, Hôpital Beaujon, UTAMA, Clichy 92110, France
| | - Jean-Baptiste Trabut
- APHP, Hôpitaux Universitaires Henri Mondor, DMU IMPACT, Hôpital Emile ROUX, Service d'addictologie, Limeil Brévannes 94450, France
| | - Isabelle Kousignian
- EA 7537 BioSTM, Faculté de Pharmacie, Université Paris Descartes, USPC, Paris 75006, France
| | - Luana Boumendil
- EA 7537 BioSTM, Faculté de Pharmacie, Université Paris Descartes, USPC, Paris 75006, France
| | - Eric Vicaut
- APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Unité de Recherche Clinique, Paris 75010, France
| | - Nathalie Prince
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France
| | - Jean-Louis Laplanche
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Lariboisière, DMU BioGeM, Département de Biochimie et Biologie Moléculaire, Paris 75010, France
| | - Frank Bellivier
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France
| | - Jean-Pierre Lépine
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France
| | - Cynthia Marie-Claire
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France
| | - Georges Brousse
- CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Service d'Addictologie et Université d'Auvergne EA 7280, UFR de Médecine, Clermont-Ferrand 63000, France
| | - Florence Vorspan
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France
| | - Vanessa Bloch
- Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Pharmacie Hospitalière, Paris 75010, France
| |
Collapse
|
2
|
Icick R, Karsinti E, Brousse G, Chrétienneau C, Trabut JB, Belforte B, Coeuru P, Moisan D, Deschenau A, Cottencin O, Gay A, Lack P, Pelissier-Alicot AL, Dupuy G, Fortias M, Etain B, Lépine JP, Laplanche JL, Bellivier F, Vorspan F, Bloch V. Childhood trauma and the severity of past suicide attempts in outpatients with cocaine use disorders. Subst Abus 2021; 43:623-632. [PMID: 34597243 DOI: 10.1080/08897077.2021.1975875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Suicide attempts have been associated with both cocaine use disorder (CocUD) and childhood trauma. We investigated how childhood trauma is an independent risk factor for serious and recurrent suicide attempts in CocUD. Method: 298 outpatients (23% women) with CocUD underwent standardized assessments of substance dependence (Diagnostic and Statistical Manual-mental disorders, fourth edition, text revised), impulsiveness, resilience, and childhood trauma, using validated tools. Suicide attempts history was categorized as single vs. recurrent or non-serious vs. serious depending on the lifetime number of suicide attempts and the potential or actual lethality of the worst attempt reported, respectively. Bivariate and multinomial regression analyses were used to characterize which childhood trauma patterns were associated with the suicide attempts groups. Results: 58% of CocUD patients reported childhood trauma. Recurrent and serious suicide attempts clustered together and were thus combined into "severe SA." Severe suicide attempt risk increased proportionally to the number of childhood traumas (test for trend, p = 9 × 10-7). Non-severe suicide attempt risk increased with impulsiveness and decreased with resilience. In multinomial regression models, a higher number of traumas and emotional abuse were independently and only associated with severe vs. non-severe suicide attempts (effect size = 0.82, AUC = 0.7). The study was limited by its cross-sectional design. Conclusion: These preferential associations between childhood trauma and severe suicide attempts warrant specific monitoring of suicide attempts risk in CocUD, regardless of the severity of addiction profiles.
Collapse
Affiliation(s)
- Romain Icick
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France.,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France.,INSERM UMR-S1144, Université de Paris, Paris, France
| | - Emily Karsinti
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France.,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France.,ED139, Laboratoire CLIPSYD, Paris Nanterre University, Nanterre, France
| | - Georges Brousse
- INSERM UMR-1107, Neuro-Dol, Université Clermont-Auvergne, Clermont-Ferrand, France
| | - Clara Chrétienneau
- INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France
| | | | - Beatriz Belforte
- APHP, Hôpital Européen Georges Pompidou, CSAPA Monte-Cristo, Paris, France
| | | | | | | | - Olivier Cottencin
- Université de Lille, CHU Lille - Psychiaty and Addiction Medicine Department, INSERM U1172 - Lille Neuroscience & Cognition Centre (LiNC), Plasticity & SubjectivitY team, Lille, France
| | - Aurélia Gay
- Service d'Addictologie, CHU St Etienne, Saint Etienne, France
| | | | | | - Gaël Dupuy
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France
| | - Maeva Fortias
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France
| | - Bruno Etain
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France.,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France.,INSERM UMR-S1144, Université de Paris, Paris, France
| | - Jean-Pierre Lépine
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France.,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France.,INSERM UMR-S1144, Université de Paris, Paris, France
| | - Jean-Louis Laplanche
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France.,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France.,INSERM UMR-S1144, Université de Paris, Paris, France
| | - Frank Bellivier
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France.,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France.,INSERM UMR-S1144, Université de Paris, Paris, France
| | - Florence Vorspan
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France.,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France.,INSERM UMR-S1144, Université de Paris, Paris, France
| | - Vanessa Bloch
- Département de Psychiatrie et de Médecine Addictologique, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France.,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France.,INSERM UMR-S1144, Université de Paris, Paris, France
| |
Collapse
|
3
|
Icick R, Bloch V, Prince N, Karsinti E, Lépine JP, Laplanche JL, Mouly S, Marie-Claire C, Brousse G, Bellivier F, Vorspan F. Clustering suicidal phenotypes and genetic associations with brain-derived neurotrophic factor in patients with substance use disorders. Transl Psychiatry 2021; 11:72. [PMID: 33479229 PMCID: PMC7820499 DOI: 10.1038/s41398-021-01200-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 06/13/2020] [Accepted: 07/03/2020] [Indexed: 11/09/2022] Open
Abstract
Suicide attempts (SA), especially recurrent SA or serious SA, are common in substance use disorders (SUD). However, the genetic component of SA in SUD samples remains unclear. Brain-derived neurotrophic factor (BDNF) alleles and levels have been repeatedly involved in stress-related psychopathology. This investigation uses a within-cases study of BDNF and associated factors in three suicidal phenotypes ('any', 'recurrent', and 'serious') of outpatients seeking treatment for opiate and/or cocaine use disorder. Phenotypic characterization was ascertained using a semi-structured interview. After thorough quality control, 98 SNPs of BDNF and associated factors (the BDNF pathway) were extracted from whole-genome data, leaving 411 patients of Caucasian ancestry, who had reliable data regarding their SA history. Binary and multinomial regression with the three suicidal phenotypes were further performed to adjust for possible confounders, along with hierarchical clustering and compared to controls (N = 2504). Bayesian analyses were conducted to detect pleiotropy across the suicidal phenotypes. Among 154 (37%) ever suicide attempters, 104 (68%) reported at least one serious SA and 96 (57%) two SA or more. The median number of non-tobacco SUDs was three. The BDNF gene remained associated with lifetime SA in SNP-based (rs7934165, rs10835210) and gene-based tests within the clinical sample. rs10835210 clustered with serious SA. Bayesian analysis identified genetic correlation between 'any' and 'serious' SA regarding rs7934165. Despite limitations, 'serious' SA was shown to share both clinical and genetic risk factors of SA-not otherwise specified, suggesting a shared BDNF-related pathophysiology of SA in this population with multiple SUDs.
Collapse
Affiliation(s)
- Romain Icick
- Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Paris, France. .,INSERM U1144, "Therapeutic Optimization in Neuropsychopharmacology", Paris, France. .,Université de Paris, Inserm UMR-S1144, Paris, France.
| | - Vanessa Bloch
- grid.50550.350000 0001 2175 4109Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Paris, France ,grid.7429.80000000121866389INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France ,Université de Paris, Inserm UMR-S1144, Paris, France
| | - Nathalie Prince
- grid.7429.80000000121866389INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France ,Université de Paris, Inserm UMR-S1144, Paris, France
| | - Emily Karsinti
- grid.50550.350000 0001 2175 4109Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Paris, France ,grid.7429.80000000121866389INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France ,ED139, Paris Nanterre University, Nanterre, France
| | - Jean-Pierre Lépine
- grid.50550.350000 0001 2175 4109Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Paris, France ,grid.7429.80000000121866389INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France ,Université de Paris, Inserm UMR-S1144, Paris, France
| | - Jean-Louis Laplanche
- grid.50550.350000 0001 2175 4109Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Paris, France
| | - Stéphane Mouly
- grid.50550.350000 0001 2175 4109Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Paris, France ,grid.7429.80000000121866389INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France ,Université de Paris, Inserm UMR-S1144, Paris, France
| | - Cynthia Marie-Claire
- grid.7429.80000000121866389INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France ,Université de Paris, Inserm UMR-S1144, Paris, France
| | - Georges Brousse
- grid.494717.80000000115480420Inserm UMR-1107, Neuro-Dol, Université Clermont-Auvergne, Clermont-Ferrand, France
| | - Frank Bellivier
- grid.50550.350000 0001 2175 4109Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Paris, France ,grid.7429.80000000121866389INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France ,Université de Paris, Inserm UMR-S1144, Paris, France
| | - Florence Vorspan
- grid.50550.350000 0001 2175 4109Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Paris, France ,grid.7429.80000000121866389INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France ,Université de Paris, Inserm UMR-S1144, Paris, France
| |
Collapse
|
4
|
Faytout M, Tignol J, Swendsen J, Grabot D, Aouizerate B, Lépine JP. Social phobia, fear of negative evaluation and harm avoidance. Eur Psychiatry 2020; 22:75-9. [PMID: 17101266 DOI: 10.1016/j.eurpsy.2005.07.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2005] [Accepted: 09/17/2005] [Indexed: 10/23/2022] Open
Abstract
AbstractThis naturalistic, prospective investigation examined the role of fear of negative evaluation and the personality trait of harm avoidance in the anxiety levels of treated social phobia patients. One hundred and fifty-seven patients with DSM-IV social phobia were assessed before starting treatment and were then followed for up to two years. As expected, greater fear of negative evaluation and higher scores of harm avoidance were associated with greater anxiety at the 6 month follow-up, and harm avoidance remained a significant predictor at 24 months. However, no evidence was found for an interaction between the personality and cognitive variables examined. The findings are discussed in terms of the relative independence of these factors, as well as their potential implications for the treatment of this disorder.
Collapse
Affiliation(s)
- M Faytout
- Adult Psychiatry Service, Hôpital Charles Perrens, Bordeaux, France.
| | | | | | | | | | | |
Collapse
|
5
|
Husky MM, Bharat C, Lépine JP, Kovess-Masfety V. Cohort Alcohol Use in France and the Transition from Use to Alcohol Use Disorder and Remission. J Psychoactive Drugs 2019; 51:453-462. [PMID: 31076020 DOI: 10.1080/02791072.2019.1612536] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The study aimed to examine the age of onset of stages of alcohol use in the general population, and to estimate the association of cohort use with the probability of transitioning from alcohol use to alcohol use disorder (AUD) and remission. French data (N = 2,894) from the European Study of the Epidemiology of Mental Disorders Survey and collected in 2000 were used. Data on lifetime history of alcohol use and DSM-IV alcohol use disorders, and remission were collected. Nearly every adult has consumed alcohol at least once in their lifetime (92.8%), and among users, 88.3% developed regular use, 6.0% met criteria for abuse and 1.7% for dependence. One-third of the population (32.8%) had used alcohol by the age of 15. Over 85% of cases of regular use were established prior to age 25, as were 61.1% of abuse and 39.4% of dependence cases. The proportion of people in an individual's age and sex cohort who had already used alcohol by a given age was positively and significantly associated with increased odds of transitioning to each stage examined. The findings highlight sensitive periods of life where persons are at greater risk for transitioning to a higher level of alcohol use, and underscore the importance of cohort use in transition risk.
Collapse
Affiliation(s)
- Mathilde M Husky
- Institut Universitaire de France, Université de Bordeaux, Laboratoire de Psychologie EA4139, Bordeaux, France
| | - Chrianna Bharat
- National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia
| | - Jean-Pierre Lépine
- Inserm UMR-S 1144, Hôpital Saint-Louis Lariboisière Fernand Widal, Fernand-Widal, Paris, France
| | - Viviane Kovess-Masfety
- Ecole des Hautes Etudes en Santé Publique, Institut de Psychologie de Paris Descartes (EA 4057), Paris, France
| |
Collapse
|
6
|
Hamdani N, Bengoufa D, Godin O, Doukhan R, Le Guen E, Daban-Huard C, Bennabi M, Delavest M, Lépine JP, Boukouaci W, Laouamri H, Houenou J, Jamain S, Richard JR, Lecorvosier P, Yolken R, Rajagopal K, Leboyer M, Tamouza R. Immunoglobulin sub-class distribution in bipolar disorder and schizophrenia: potential relationship with latent Toxoplasma Gondii infection. BMC Psychiatry 2018; 18:239. [PMID: 30053866 PMCID: PMC6062947 DOI: 10.1186/s12888-018-1821-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Accepted: 07/17/2018] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Immune dysfunction could play a significant role in the pathogenesis of bipolar disorder (BD) and schizophrenia (SZ), conditions with an underlying pro-inflammatory state. Studies on humoral immune responses (which reflects antibody mediated fight against pathogens) in schizophrenia and bipolar disorder are sparse and often providing contradictory results. The aim of this study was to assess humoral immunity in a group of stable bipolar disorder and schizophrenia patients compared to controls by determining total Immunoglobulins and IgG subclasses and to assess their association with latent Toxoplasma gondii and/or CMV infection. METHODS 334 subjects (124 BD, 75 SZ and 135 Healthy Controls [HC]) were included and tested for humoral immunity by determining the total immunoglobulins (IgG,A and M) and IgG subclasses (IgG1, IgG2, IgG3, IgG4) and their relationship with latent Toxoplasma gondii infection, an established risk factor for BD and SZ. RESULTS Although lower levels of IgG, IgG1, IgG2, IgG4 and IgA were found among BD as compared to HC and/or SZ, after adjustment for confounding variables, only low levels of IgG and IgG1 in BD remai- ned significant. Strikingly highest levels of antibodies to T. gondii (but not CMV) infection in BD and SZ were associated with lowest levels of IgG3 and IgG4 levels as compared to controls. CONCLUSIONS Schizophrenia and bipolar disorder patients with latent T. gondii specific infection may be more vulnerable to changes in immuno-inflammatory processes than controls with similar latent infectious state. Simultaneous sequential immunological monitoring both in steady state and active disease phases in the same BD and SZ patients are warranted to understand the role of Toxoplasma gondii latency in these disorders.
Collapse
Affiliation(s)
- Nora Hamdani
- Inserm U955, Team 15 «Genetic Psychiatry », F-94000, Creteil, France. .,AP-HP, DHU Pe-PSY, Paris Est Créteil University, Henri Mondor - Albert Chenevier, Group, psyChiatry, F-94000, Creteil, France. .,Fondation Fondamental, Scientific Cooperation Foundation, F-94010, Creteil, France.
| | - Djaouida Bengoufa
- 0000 0001 2217 0017grid.7452.4Jean Dausset Laboratory, LabEx Transplantex & INSERM, UMRS 1160 Saint Louis Hospital, Paris Diderot University, F75010 Paris, France
| | - Ophélia Godin
- 0000 0004 0386 3258grid.462410.5Inserm U955, Team 15 «Genetic Psychiatry », F-94000 Creteil, France ,grid.484137.dFondation Fondamental, Scientific Cooperation Foundation, F-94010 Creteil, France
| | - Raphaël Doukhan
- AP-HP, DHU Pe-PSY, Paris Est Créteil University, Henri Mondor - Albert Chenevier, Group, psyChiatry, F-94000 Creteil, France
| | - Emmanuel Le Guen
- 0000 0004 0386 3258grid.462410.5Inserm U955, Team 15 «Genetic Psychiatry », F-94000 Creteil, France ,AP-HP, DHU Pe-PSY, Paris Est Créteil University, Henri Mondor - Albert Chenevier, Group, psyChiatry, F-94000 Creteil, France
| | - Claire Daban-Huard
- 0000 0004 0386 3258grid.462410.5Inserm U955, Team 15 «Genetic Psychiatry », F-94000 Creteil, France ,AP-HP, DHU Pe-PSY, Paris Est Créteil University, Henri Mondor - Albert Chenevier, Group, psyChiatry, F-94000 Creteil, France ,grid.484137.dFondation Fondamental, Scientific Cooperation Foundation, F-94010 Creteil, France
| | - Meriem Bennabi
- 0000 0001 2217 0017grid.7452.4Jean Dausset Laboratory, LabEx Transplantex & INSERM, UMRS 1160 Saint Louis Hospital, Paris Diderot University, F75010 Paris, France
| | - Marine Delavest
- AP-HP, Paris Diderot University, Psychiatry, Lariboisiere Fernand Widal Hospital, F-75010 Paris, France
| | - Jean-Pierre Lépine
- AP-HP, Paris Diderot University, Psychiatry, Lariboisiere Fernand Widal Hospital, F-75010 Paris, France
| | - Wahid Boukouaci
- 0000 0001 2217 0017grid.7452.4Jean Dausset Laboratory, LabEx Transplantex & INSERM, UMRS 1160 Saint Louis Hospital, Paris Diderot University, F75010 Paris, France
| | - Hakim Laouamri
- grid.484137.dFondation Fondamental, Scientific Cooperation Foundation, F-94010 Creteil, France
| | - Josselin Houenou
- 0000 0004 0386 3258grid.462410.5Inserm U955, Team 15 «Genetic Psychiatry », F-94000 Creteil, France ,AP-HP, DHU Pe-PSY, Paris Est Créteil University, Henri Mondor - Albert Chenevier, Group, psyChiatry, F-94000 Creteil, France ,grid.484137.dFondation Fondamental, Scientific Cooperation Foundation, F-94010 Creteil, France ,grid.457334.2CEA Saclay, Neurospin, Gif-Sur-Yvette, France
| | - Stéphane Jamain
- 0000 0004 0386 3258grid.462410.5Inserm U955, Team 15 «Genetic Psychiatry », F-94000 Creteil, France ,grid.484137.dFondation Fondamental, Scientific Cooperation Foundation, F-94010 Creteil, France
| | - Jean-Romain Richard
- 0000 0004 0386 3258grid.462410.5Inserm U955, Team 15 «Genetic Psychiatry », F-94000 Creteil, France ,grid.484137.dFondation Fondamental, Scientific Cooperation Foundation, F-94010 Creteil, France
| | - Philippe Lecorvosier
- 0000 0001 2175 4109grid.50550.35CIC 006Henri Mondor INSERM & Biological Resource Platform, Paris Est University, AP-HP, Creteil, France
| | - Robert Yolken
- 0000 0004 0442 9875grid.411940.9Stanley Laboratory of Developmental Neurovirology, Johns Hopkins University Medical Center, Baltimore, USA
| | | | - Marion Leboyer
- 0000 0004 0386 3258grid.462410.5Inserm U955, Team 15 «Genetic Psychiatry », F-94000 Creteil, France ,AP-HP, DHU Pe-PSY, Paris Est Créteil University, Henri Mondor - Albert Chenevier, Group, psyChiatry, F-94000 Creteil, France ,grid.484137.dFondation Fondamental, Scientific Cooperation Foundation, F-94010 Creteil, France
| | - Ryad Tamouza
- grid.484137.dFondation Fondamental, Scientific Cooperation Foundation, F-94010 Creteil, France ,0000 0001 2217 0017grid.7452.4Jean Dausset Laboratory, LabEx Transplantex & INSERM, UMRS 1160 Saint Louis Hospital, Paris Diderot University, F75010 Paris, France
| |
Collapse
|
7
|
Martinez L, Vorspan F, Declèves X, Azuar J, Fortias M, Questel F, Dereux A, Grichy L, Barreteau H, Bellivier F, Lépine JP, Bloch V. An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with vs. without chronic pretreatment with high-dosage baclofen. Fundam Clin Pharmacol 2018; 32:200-205. [DOI: 10.1111/fcp.12339] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Revised: 11/13/2017] [Accepted: 12/05/2017] [Indexed: 12/18/2022]
Affiliation(s)
- Laura Martinez
- Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Service de Pharmacie; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Florence Vorspan
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| | - Xavier Declèves
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| | - Julien Azuar
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Maeva Fortias
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Franck Questel
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Alexandra Dereux
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Leslie Grichy
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Hélène Barreteau
- Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Service de Pharmacie; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Frank Bellivier
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| | - Jean-Pierre Lépine
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| | - Vanessa Bloch
- Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Service de Pharmacie; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| |
Collapse
|
8
|
Marie-Claire C, Jourdaine C, Lépine JP, Bellivier F, Bloch V, Vorspan F. Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives. Pharmacogenomics 2017; 18:1359-1372. [DOI: 10.2217/pgs-2017-0040] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Current treatments of opioid addiction include primarily maintenance medications such as methadone. Chronic exposure to opiate and/or long-lasting maintenance treatment induce modulations of gene expression in brain and peripheral tissues. There is increasing evidence that epigenetic modifications underlie these modulations. This review summarizes published results on opioid-induced epigenetic changes in animal models and in patients. The epigenetic modifications observed with other drugs of abuse often used by opiate abusers are also outlined. Specific methadone maintenance treatment induced epigenetic modifications at different treatment stages may be combined with the ones resulting from patients’ substance use history. Therefore, research comparing groups of addicts with similar history and substances use disorders but contrasting for well-characterized treatment phenotypes should be encouraged.
Collapse
Affiliation(s)
- Cynthia Marie-Claire
- Variabilité de réponse aux psychotropes, INSERMU1144/Faculté de Pharmacie de Paris/Université Paris Descartes/Université ParisDiderot/Université Sorbonne Paris Cité, Paris, France
| | - Clément Jourdaine
- AP-HP, GH Saint-Louis – Lariboisière – F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris cedex 10, France
| | - Jean-Pierre Lépine
- AP-HP, GH Saint-Louis – Lariboisière – F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris cedex 10, France
| | - Frank Bellivier
- Variabilité de réponse aux psychotropes, INSERMU1144/Faculté de Pharmacie de Paris/Université Paris Descartes/Université ParisDiderot/Université Sorbonne Paris Cité, Paris, France
- AP-HP, GH Saint-Louis – Lariboisière – F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris cedex 10, France
| | - Vanessa Bloch
- Variabilité de réponse aux psychotropes, INSERMU1144/Faculté de Pharmacie de Paris/Université Paris Descartes/Université ParisDiderot/Université Sorbonne Paris Cité, Paris, France
| | - Florence Vorspan
- Variabilité de réponse aux psychotropes, INSERMU1144/Faculté de Pharmacie de Paris/Université Paris Descartes/Université ParisDiderot/Université Sorbonne Paris Cité, Paris, France
- AP-HP, GH Saint-Louis – Lariboisière – F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris cedex 10, France
| |
Collapse
|
9
|
Hamdani N, Daban-Huard C, Godin O, Laouamri H, Jamain S, Attiba D, Delavest M, Lépine JP, Le Corvoisier P, Houenou J, Richard JR, Yolken RH, Krishnamoorthy R, Tamouza R, Leboyer M, Dickerson FB. Effects of Cumulative Herpesviridae and Toxoplasma gondii Infections on Cognitive Function in Healthy, Bipolar, and Schizophrenia Subjects. J Clin Psychiatry 2017; 78:e18-e27. [PMID: 27929612 DOI: 10.4088/jcp.15m10133] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 01/19/2016] [Indexed: 10/20/2022]
Abstract
OBJECTIVE Schizophrenia and bipolar disorder are associated with cognitive impairment leading to social disruption. While previous studies have focused on the effect of individual infectious exposure, namely, Herpesviridae viruses or Toxoplasma gondii (T gondii), on cognitive functioning, the objective of the present study was to examine the effect of multiple infections on cognitive functioning in patients with schizophrenia and bipolar disorder and in healthy controls. METHODS Seropositivity to herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), cytomegalovirus (CMV), and T gondii was related to cognitive status among 423 participants (recruited between 2008 and 2014; 138 patients with bipolar disorder, 105 patients with schizophrenia [DSM-IV criteria], and 180 healthy controls) for episodic verbal memory (California Verbal Learning Test), working memory (Wechsler Adult Intelligence Scale, third edition), and premorbid intelligence quotient (National Adult Reading Test). RESULTS Seropositivity to and antibody levels of HSV-1 were significantly associated with working memory, which persisted after correction (backward digit span: β = -0.10 [0.05], χ² = 33.89, P = .0001) in the overall sample. This association was particularly strong in the control group (β = -0.18 [0.08], P = .04, Z = -3.55, P = .0008; corrected P = .012). Further, cumulative exposure to HSV-1, HSV-2, and CMV viruses and T gondii parasite was also associated with lower scores on working memory as measured by backward digit span in the overall sample (Z = 2.86, P = .004; Z = 2.47, P = .01; and Z = 3.35, P = .01, respectively). CONCLUSIONS Exposures to Herpesviridae and T gondii parasite seem to impact cognitive functioning. Because infections caused by Herpesviridae and/or T gondii parasite are quite common in the (general) population, assessing and confirming the cognitive impairment among those who have cumulative exposures is useful and of interest.
Collapse
Affiliation(s)
- Nora Hamdani
- Pole de Psychiatrie et d'Addictologie des Hôpitaux Universitaires Henri Mondor, Hôpital A Chenevier, 40 rue de Mesly, Créteil 94000, France. .,Inserm U955, Team 15 (Genetic Psychiatry), Créteil, France.,AP-HP, DHU Pe PSY, Paris-Est Créteil University, Henri Mondor-Albert Chenevier group, Psychiatry, Créteil, France.,Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France
| | - Claire Daban-Huard
- Inserm U955, Team 15 (Genetic Psychiatry), Créteil, France.,AP-HP, DHU Pe PSY, Paris-Est Créteil University, Henri Mondor-Albert Chenevier group, Psychiatry, Créteil, France.,Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France
| | - Ophelia Godin
- Inserm U955, Team 15 (Genetic Psychiatry), Créteil, France.,Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France
| | - Hakim Laouamri
- Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France
| | - Stéphane Jamain
- Inserm U955, Team 15 (Genetic Psychiatry), Créteil, France.,Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France
| | - Dodji Attiba
- Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France
| | - Marine Delavest
- AP-HP, Paris Diderot University, Psychiatry, Lariboisiere Fernand Widal Hospital, Paris, France
| | - Jean-Pierre Lépine
- AP-HP, Paris Diderot University, Psychiatry, Lariboisiere Fernand Widal Hospital, Paris, France
| | - Philippe Le Corvoisier
- CIC 006 Henri Mondor Inserm and Biological Resource Platform, Paris Est University, Créteil, France
| | - Josselin Houenou
- Inserm U955, Team 15 (Genetic Psychiatry), Créteil, France.,AP-HP, DHU Pe PSY, Paris-Est Créteil University, Henri Mondor-Albert Chenevier group, Psychiatry, Créteil, France.,Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France.,CEA Saclay, Neurospin, Gif-Sur-Yvette, France
| | - Jean-Romain Richard
- Inserm U955, Team 15 (Genetic Psychiatry), Créteil, France.,Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France
| | - Robert H Yolken
- Stanley Laboratory of Developmental Neurovirology, Johns Hopkins University Medical Center, Baltimore, Maryland, USA
| | | | - Ryad Tamouza
- Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France.,Jean Dausset Laboratory, LabEx Transplantex and Inserm, UMRS Paris Diderot University, Paris, France
| | - Marion Leboyer
- Inserm U955, Team 15 (Genetic Psychiatry), Créteil, France.,AP-HP, DHU Pe PSY, Paris-Est Créteil University, Henri Mondor-Albert Chenevier group, Psychiatry, Créteil, France.,Fondation Fondamental, Scientific Cooperation Foundation, Créteil, France
| | | |
Collapse
|
10
|
Karsinti E, Fortias M, Dupuy G, Ksouda K, Laqueille X, Simonpoli AM, Touzeau D, Avril E, Orizet C, Belforte B, Coeuru P, Polomeni P, Icick R, Jarroir M, Bloch V, Scott J, Lépine JP, Bellivier F, Vorspan F. Anxiety disorders are associated with early onset of heroin use and rapid transition to dependence in methadone maintained patients. Psychiatry Res 2016; 245:423-426. [PMID: 27620325 DOI: 10.1016/j.psychres.2016.04.064] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Revised: 03/14/2016] [Accepted: 04/20/2016] [Indexed: 11/19/2022]
Abstract
Early onset of heroin use is a severity marker of heroin use disorder. We studied the interaction between early onset and rapid transition to heroin dependence recorded with retrospective interviews in 213 patients with severe heroin dependence and history of methadone maintenance treatment. General linear models were used to identify independent factors associated with early onset, factors associated with rapid transition to dependence, and a multivariate model was used to study the interaction of those two dimensions. Lifetime history of anxiety disorders and age at onset of cannabis use are shared common risk factors and are associated with the interaction.
Collapse
Affiliation(s)
- Emily Karsinti
- APHP, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France.
| | - Maeva Fortias
- APHP, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France
| | - Gaël Dupuy
- APHP, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France
| | - Kamilia Ksouda
- Laboratoire de Pharmacologie, Faculté de Médecine de Sfax, Tunisia
| | - Xavier Laqueille
- Centre Hospitalier Sainte-Anne, Service d'addictologie, 1, rue Cabanis, Paris, France
| | | | - Didier Touzeau
- APHP, Hôpital Paul Guiraud, CSAPA Clinique Liberté, Ivry-sur-Seine, France
| | | | - Cyrille Orizet
- APHP, Hôpital Européen Georges Pompidou, CSAPA Monte-Cristo, Paris, France
| | - Beatriz Belforte
- APHP, Hôpital Européen Georges Pompidou, CSAPA Monte-Cristo, Paris, France
| | | | | | - Romain Icick
- APHP, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France
| | - Marine Jarroir
- APHP, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France
| | - Vanessa Bloch
- Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France
| | - Jan Scott
- Academic Psychiatry, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK; Centre for Affective Disorders, Institute of Psychiatry, London, UK
| | - Jean-Pierre Lépine
- APHP, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France
| | - Frank Bellivier
- APHP, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France
| | - Florence Vorspan
- APHP, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S 1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris, F-75013, France
| |
Collapse
|
11
|
Vorspan F, Fortias M, Zerdazi EH, Karsinti E, Bloch V, Lépine JP, Bellivier F, Brousse G, van den Brink W, Derks EM. Self-reported cue-induced physical symptoms of craving as an indicator of cocaine dependence. Am J Addict 2015; 24:740-3. [PMID: 26541796 DOI: 10.1111/ajad.12303] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Revised: 10/14/2015] [Accepted: 10/24/2015] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND The presence of cocaine dependence is under-recognized by cocaine users and requires a careful standardized interview to be ascertained by clinicians. OBJECTIVE To test if past experiences of cue-induced physical symptoms of craving (nausea, vomiting, sweating, shaking, nervousness) before cocaine use could be a useful way to boost the diagnosis of cocaine dependence. METHODS A cross-sectional study of 221 cocaine users from several outpatient addiction treatment services in France, addressing the most severe period of cocaine use. DSM-IV cocaine dependence was determined with the MINI International Neuropsychiatric Interview (MINI). Physical symptoms before using cocaine were retrospectively assessed with a single item rated on a 0-5 scale. RESULTS The prevalence of DSM-IV cocaine dependence was 84.6%. The mean score on the physical symptoms item was 1.3 (SD 1.3). A cut-off score of ≥ 1 on this item alone resulted in a sensitivity of 62%, a specificity of 88.2%, a positive predictive value of 96.6% and a negative predictive value of 29.7% to detect DSM IV cocaine dependence in this sample. Adding this item to a model with the frequency of cocaine use significantly increased the predictive power: Nagelkerke's R(2) increased from .149 to .326 (p < .001). DISCUSSION AND CONCLUSION Recalling past experiences of cue-induced physical signs of cocaine craving is associated with a clinical diagnosis of lifetime cocaine dependence and could be a simple way to improve its detection in clinical settings.
Collapse
Affiliation(s)
- Florence Vorspan
- APHP, Hôpital Fernand Widal, Service de Médecine Addictologique, Paris, France.,Faculté de Médecine, Université Paris Diderot, Paris, France.,Inserm U1144, Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France.,Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherland
| | - Maeva Fortias
- APHP, Hôpital Fernand Widal, Service de Médecine Addictologique, Paris, France.,Faculté de Médecine, Université Paris Diderot, Paris, France
| | - El-Hadi Zerdazi
- Inserm U1144, Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France
| | - Emily Karsinti
- Inserm U1144, Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France
| | - Vanessa Bloch
- Inserm U1144, Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France
| | - Jean-Pierre Lépine
- APHP, Hôpital Fernand Widal, Service de Médecine Addictologique, Paris, France.,Faculté de Médecine, Université Paris Diderot, Paris, France.,Inserm U1144, Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France
| | - Frank Bellivier
- APHP, Hôpital Fernand Widal, Service de Médecine Addictologique, Paris, France.,Faculté de Médecine, Université Paris Diderot, Paris, France.,Inserm U1144, Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France
| | - Georges Brousse
- Psychiatry B-Department of Addictology, Université Clermont 1, UFR Médecine, EA7280, Clermont-Ferrand, and CHU Clermont-Ferrand, Clermont-Ferrand, F-63003, France
| | - Wim van den Brink
- Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherland
| | - Eske M Derks
- Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherland
| |
Collapse
|
12
|
Corruble E, El Asmar K, Trabado S, Verstuyft C, Falissard B, Colle R, Petit AC, Gressier F, Brailly-Tabard S, Ferreri F, Lépine JP, Haffen E, Polosan M, Bourrier C, Perlemuter G, Chanson P, Fève B, Becquemont L. Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort. World Psychiatry 2015; 14:366-7. [PMID: 26407797 PMCID: PMC4592664 DOI: 10.1002/wps.20260] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Affiliation(s)
- Emmanuelle Corruble
- University Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France
| | - Khalil El Asmar
- Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France
| | - Severine Trabado
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-S1185Le Kremlin Bicêtre, France
| | - Céline Verstuyft
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale U1184Le Kremlin Bicêtre, France
| | - Bruno Falissard
- University Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital Paul BrousseVillejuif, France
| | - Romain Colle
- University Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France
| | - Anne-Cécile Petit
- Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France
| | - Florence Gressier
- University Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France
| | - Sylvie Brailly-Tabard
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-S1185Le Kremlin Bicêtre, France
| | - Florian Ferreri
- Université Pierre et Marie CurieParis, France,Service de Psychiatrie, Hôpital Saint-AntoineParis, France
| | | | | | | | - Céline Bourrier
- Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France
| | - Gabriel Perlemuter
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-996Clamart, France,Hôpital Antoine-BéclèreClamart, France
| | - Philippe Chanson
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-S1185Le Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale U1185Le Kremlin Bicêtre, France
| | - Bruno Fève
- Service de Psychiatrie, Hôpital Saint-AntoineParis, France,Institut Hospitalo-Universitaire ICANParis, France,Service d’Endocrinologie, Hôpital Saint-AntoineParis, France
| | - Laurent Becquemont
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale U1184Le Kremlin Bicêtre, France
| |
Collapse
|
13
|
Icick R, Peoc'h K, Karsinti E, Ksouda K, Hajj A, Bloch V, Prince N, Mouly S, Bellivier F, Lépine JP, Laplanche JL, Vorspan F. A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients. Am J Addict 2015; 24:613-20. [PMID: 26331953 DOI: 10.1111/ajad.12273] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2015] [Revised: 07/23/2015] [Accepted: 08/08/2015] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND AND OBJECTIVES The burden of opiate dependence not only relies on somatic complications such as infectious diseases or acute intoxication but also on frequent psychiatric events such as major depressive disorder (MDD) and suicidal behavior (SB). Given the preclinical and clinical evidence regarding the associations between cannabinoid systems and both opiate dependence and psychiatric disorders, we chose to address whether one single nucleotide polymorphism (SNP) of the cannabinoid receptor type 1 gene (CNR1) named rs2023239 would be associated with lifetime MDD and SB in a population of opiate-dependent outpatients remitted under stable methadone treatment. METHODS Sociodemographic and clinical data were included as independent factors in two logistic regression models aimed at predicting SB and MDD, respectively, performed with 85 Caucasian individuals. RESULTS The minor C allele of rs2023239 showed an independent protective effect against lifetime MDD after adjustment for potential confounders. It was not associated with variables related to suicidal behavior. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE Despite limitations due to the modest sample size, our results are consistent with previous research on the endocannabinoid system and suggest new leads for detecting subjects at risk of MDD, which remains insufficiently diagnosed and treated in patients suffering from severe addictive disorders.
Collapse
Affiliation(s)
- Romain Icick
- Department of Psychiatry and Addiction Medicine, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,Inserm UMR-S1144, Paris, France.,Paris Descartes University, Paris, France
| | - Katell Peoc'h
- Inserm UMR-S1144, Paris, France.,Paris Descartes University, Paris, France.,Paris Diderot University, Paris, France.,Department of Biochemistry and Molecular Biology, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, AP-HP, Paris, France
| | - Emily Karsinti
- Department of Psychiatry and Addiction Medicine, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,Inserm UMR-S1144, Paris, France
| | | | - Aline Hajj
- Inserm UMR-S1144, Paris, France.,Paris Descartes University, Paris, France
| | - Vanessa Bloch
- Inserm UMR-S1144, Paris, France.,Hospital Pharmacy, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, AP-HP, Paris, France
| | - Nathalie Prince
- Inserm UMR-S1144, Paris, France.,Department of Biochemistry and Molecular Biology, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, AP-HP, Paris, France
| | - Stéphane Mouly
- Inserm UMR-S1144, Paris, France.,Paris Descartes University, Paris, France.,Paris Diderot University, Paris, France.,Department of Internal Medicine, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Frank Bellivier
- Department of Psychiatry and Addiction Medicine, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,Inserm UMR-S1144, Paris, France.,Paris Descartes University, Paris, France.,Paris Diderot University, Paris, France
| | - Jean-Pierre Lépine
- Department of Psychiatry and Addiction Medicine, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,Inserm UMR-S1144, Paris, France.,Paris Descartes University, Paris, France.,Paris Diderot University, Paris, France
| | - Jean-Louis Laplanche
- Inserm UMR-S1144, Paris, France.,Paris Descartes University, Paris, France.,Paris Diderot University, Paris, France.,Department of Biochemistry and Molecular Biology, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, AP-HP, Paris, France
| | - Florence Vorspan
- Department of Psychiatry and Addiction Medicine, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,Inserm UMR-S1144, Paris, France.,Paris Descartes University, Paris, France.,Paris Diderot University, Paris, France
| |
Collapse
|
14
|
Karsinti E, Jarroir M, Zerdazi EH, Bloch V, Dupuy G, Belforte B, Coeuru P, Plat A, Deschenau A, Cottencin O, Gay A, Lack P, Pelissier-Alicot AL, Bellivier F, Lépine JP, Brousse G, Vorspan F. Childhood trauma are not associated with the intensity of transient cocaine induced psychotic symptoms. Psychiatry Res 2015; 228:941-4. [PMID: 26154812 DOI: 10.1016/j.psychres.2015.05.065] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Revised: 04/29/2015] [Accepted: 05/25/2015] [Indexed: 10/23/2022]
Abstract
A personal history of childhood trauma has been associated with the severity of psychotic symptoms in several disorders. We evaluated retrospectively cocaine-induced psychotic symptoms with the SAPS-CIP and childhood trauma with the CTQ in a clinical sample of 144 cocaine users. The SAPS-CIP score was not statistically associated with the presence or number or intensity of trauma, but was associated with rapid routes of administration (intravenous and smoked) and with frequent cocaine use.
Collapse
Affiliation(s)
- Emily Karsinti
- Inserm Umr_s 1144 Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France
| | - Marine Jarroir
- APHP, Hôpital Fernand Widal, Service de Psychiatrie, CSAPA Espace Murger, Paris, France
| | - El-Hadi Zerdazi
- Inserm Umr_s 1144 Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France
| | - Vanessa Bloch
- Inserm Umr_s 1144 Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France
| | - Gaël Dupuy
- APHP, Hôpital Fernand Widal, Service de Psychiatrie, CSAPA Espace Murger, Paris, France
| | - Beatriz Belforte
- APHP, Hôpital Européen Georges Pompidou, CSAPA Monte-Cristo, Paris, France
| | | | - Arnaud Plat
- APHP, Hôpital Beaujon, UTAMA, Clichy, France
| | - Alice Deschenau
- Hôpital Paul Guiraud, CSAPA Clinique Liberté, Ivry-sur-Seine, France
| | | | - Aurelia Gay
- CHU St Etienne, Service d'Addictologie, Saint Etienne, France
| | | | | | - Frank Bellivier
- Inserm Umr_s 1144 Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France; APHP, Hôpital Fernand Widal, Service de Psychiatrie, CSAPA Espace Murger, Paris, France; APHP, Hôpital Fernand Widal, Service de Médecine Addictologique, Paris, France
| | - Jean-Pierre Lépine
- Inserm Umr_s 1144 Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France; APHP, Hôpital Fernand Widal, Service de Psychiatrie, CSAPA Espace Murger, Paris, France
| | - George Brousse
- CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Service d'Addictologie et Université d'Auvergne EA 7280, UFR de Médecine, Place Henri Dunant, Clermont-Ferrand, France
| | - Florence Vorspan
- Inserm Umr_s 1144 Variabilité de Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, France; APHP, Hôpital Fernand Widal, Service de Médecine Addictologique, Paris, France.
| |
Collapse
|
15
|
Husky MM, Lépine JP, Gasquet I, Kovess-Masfety V. Exposure to Traumatic Events and Posttraumatic Stress Disorder in France: Results From the WMH Survey. J Trauma Stress 2015; 28:275-82. [PMID: 26179388 DOI: 10.1002/jts.22020] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
This study examined the prevalence of traumatic events and the conditional probability of posttraumatic stress disorder (PTSD) associated with both specific and broad classes of events in a nationally representative sample from France. The sample (N = 1,436) was a part of the European Study of the Epidemiology of Mental Disorders Survey (ESEMeD), under the WHO World Mental Health Surveys-2000 initiative. Overall, exposure to any traumatic event was 72.7%, which appeared to be lower than what has been reported in Sweden (80.8%), similar to data from the Netherlands (71.1%), and higher than what has been reported in Spain (54.0%), Italy (56.1%), Northern Ireland (60.6%) or the U.S (55.9%). Lifetime prevalence of PTSD was 3.9%, lower than in the United States (7.8%), Sweden (5.6%), or Northern Ireland (8.8%), but higher than in Spain (2.2%) or Italy (2.4%). Being beaten up by a romantic partner (25.0%), having a child with serious illness (23.5%), and rape (21.5%) were associated with the highest risk of PTSD. The average duration of PTSD was 5.3 years (0.2-28.1). The burden of PTSD in France appeared to come from the consequences of violence and social network events suggesting that prevention efforts might focus on limiting the occurrence of exposure to avoidable events such as violence as well as provide support for persons exposed to social network events.
Collapse
Affiliation(s)
- Mathilde M Husky
- Institut de Psychologie de Paris Descartes (EA 4057), Institut Universitaire de France, Boulogne Billancourt, France
| | | | | | - Viviane Kovess-Masfety
- Ecole des Hautes Etudes en Santé Publique, Institut de Psychologie de Paris Descartes (EA 4057), Paris, France
| |
Collapse
|
16
|
Hamdani N, Daban-Huard C, Lajnef M, Gadel R, Le Corvoisier P, Delavest M, Carde S, Lépine JP, Jamain S, Houenou J, Galeh B, Richard JR, Aoki M, Charron D, Krishnamoorthy R, Yolken R, Dickerson F, Tamouza R, Leboyer M. Cognitive deterioration among bipolar disorder patients infected by Toxoplasma gondii is correlated to interleukin 6 levels. J Affect Disord 2015; 179:161-6. [PMID: 25863913 DOI: 10.1016/j.jad.2015.03.038] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Revised: 03/20/2015] [Accepted: 03/23/2015] [Indexed: 12/21/2022]
Abstract
BACKGROUND Cognitive deficits are present in a large majority of Bipolar Disorder (BD) patients and known to be a marker of bad prognosis. Because, these deficits encompass several domains and no specific medical treatment seems to be effective, it is important to better understand the mechanisms underlying cognitive deterioration. As Toxoplasma gondii is known to induce the synthesis of pro-inflammatory cytokines such as IL-6, we will explore here the possible role of T. gondii in the cognitive decline observed in BD. METHODS 42 euthymic BD patients and 36 controls were assessed for episodic verbal memory using the CVLT and for working memory and verbal ability using the WAIS III. Patients and controls were also screened for seropositivity to T. gondii and evaluated for the levels of IL-6 transcripts. RESULTS The seropositivity for T. gondii was significantly higher in BD patients as compared to controls (p=0.005). The cognitive deterioration index (DI) was higher in BD patients (p=5.10(-6)) and correlated to high IL-6 mRNA expression only among those infected by T. gondii (rho=0.43, p=0.01). Among deteriorated patients (defined by scores above 0.10 according to Weschler׳s definition), the IL-6 mRNA expression was twice greater (p=0.01). LIMITATIONS Our results are to be interpreted with caution because of our small sample size and the cross-sectional design. CONCLUSIONS A long-term exposure to inflammation, measured here with IL-6 mRNA expression in T. gondii infected BD may alter cognitive functioning. IL-6 could thus be a useful predictive marker of cognitive deterioration in BD and may help to design personalized treatment.
Collapse
Affiliation(s)
- Nora Hamdani
- Inserm U955, Equipe 15 « Psychiatrie Génétique », Créteil F-94000, France; AP-HP, DHU Pe-PSY, Université Paris Est Créteil, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie et d׳Addictologie, Créteil F-94000, France; Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France.
| | - Claire Daban-Huard
- Inserm U955, Equipe 15 « Psychiatrie Génétique », Créteil F-94000, France; AP-HP, DHU Pe-PSY, Université Paris Est Créteil, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie et d׳Addictologie, Créteil F-94000, France; Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France
| | - Mohamed Lajnef
- Inserm U955, Equipe 15 « Psychiatrie Génétique », Créteil F-94000, France; AP-HP, DHU Pe-PSY, Université Paris Est Créteil, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie et d׳Addictologie, Créteil F-94000, France; Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France
| | - Rémi Gadel
- Inserm U955, Equipe 15 « Psychiatrie Génétique », Créteil F-94000, France; AP-HP, DHU Pe-PSY, Université Paris Est Créteil, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie et d׳Addictologie, Créteil F-94000, France; Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France
| | - Philippe Le Corvoisier
- CIC 006Henri Mondor INSERM & Plateforme de Ressources Biologiques, Université Paris Est Créteil, AP-HP, France
| | - Marine Delavest
- Neurospin, UNIACT Lab, Psychiatry Team, CEA Saclay, France; AP-HP, Université Paris Diderot, Service de Psychiatrie, Hôpital Lariboisiere Fernand Widal, F-75010 Paris, France
| | - Soufiane Carde
- Inserm U955, Equipe 15 « Psychiatrie Génétique », Créteil F-94000, France; AP-HP, DHU Pe-PSY, Université Paris Est Créteil, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie et d׳Addictologie, Créteil F-94000, France; Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France; Neurospin, UNIACT Lab, Psychiatry Team, CEA Saclay, France
| | - Jean-Pierre Lépine
- Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France; AP-HP, Université Paris Diderot, Service de Psychiatrie, Hôpital Lariboisiere Fernand Widal, F-75010 Paris, France
| | - Stéphane Jamain
- Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France; AP-HP, Université Paris Diderot, Service de Psychiatrie, Hôpital Lariboisiere Fernand Widal, F-75010 Paris, France
| | - Josselin Houenou
- Inserm U955, Equipe 15 « Psychiatrie Génétique », Créteil F-94000, France; AP-HP, DHU Pe-PSY, Université Paris Est Créteil, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie et d׳Addictologie, Créteil F-94000, France; Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France; Neurospin, UNIACT Lab, Psychiatry Team, CEA Saclay, France
| | - Bijan Galeh
- CIC 006Henri Mondor INSERM & Plateforme de Ressources Biologiques, Université Paris Est Créteil, AP-HP, France
| | - Jean-Romain Richard
- Inserm U955, Equipe 15 « Psychiatrie Génétique », Créteil F-94000, France; Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France
| | - Masayuki Aoki
- Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France; Jean Dausset Dept & INSERM, UMRS 940, Hôpital Saint Louis, Univ Paris Diderot, Paris F75010, France
| | - Dominique Charron
- Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France; Jean Dausset Dept & INSERM, UMRS 940, Hôpital Saint Louis, Univ Paris Diderot, Paris F75010, France
| | | | - Robert Yolken
- Stanley Laboratory of Developmental Neurovirology, Johns Hopkins University Medical Center, Baltimore, USA
| | - Faith Dickerson
- Stanley Laboratory of Developmental Neurovirology, Johns Hopkins University Medical Center, Baltimore, USA
| | - Ryad Tamouza
- Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France; Stanley Research Program, Sheppard Pratt, Baltimore, MD, USA
| | - Marion Leboyer
- Inserm U955, Equipe 15 « Psychiatrie Génétique », Créteil F-94000, France; AP-HP, DHU Pe-PSY, Université Paris Est Créteil, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie et d׳Addictologie, Créteil F-94000, France; Fondation Fondamental, Fondation de coopération scientifique, Créteil F94000, France
| |
Collapse
|
17
|
Colle R, Gressier F, Verstuyft C, Deflesselle E, Lépine JP, Ferreri F, Hardy P, Guilloux JP, Petit AC, Fève B, Falissard B, Becquemont L, Corruble E. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J Affect Disord 2015; 175:233-40. [PMID: 25658497 DOI: 10.1016/j.jad.2015.01.013] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Revised: 01/09/2015] [Accepted: 01/12/2015] [Indexed: 10/24/2022]
Abstract
BACKGROUND Whether the Brain Derived Neurotrophic Factor (BDNF) Val66Met polymorphism can predict antidepressant drug efficacy in depressed patients remains unclear, suggesting that it may depend on antidepressant classes. We assessed the impact of Val66Met polymorphism on antidepressant response and remission depending on antidepressant classes. METHODS In a 6-month prospective, real-world setting, treatment study, 345 Caucasian depressed patients requiring a new or different drug treatment with a selective serotonin reuptake inhibitor (SSRI), a serotonin and noradrenalin reuptake inhibitor (SNRI) or a tricyclic antidepressant (TCA), were genotyped and assessed for response and remission. RESULTS 231 (67%) patients were homozygous for the Val66 allele (Val/Val) and 114 (33%) were carriers of Met allele (Met). 152 (44.1%) patients were treated with SSRI, the others with SNRI/TCA. Both response and remission were explained by interactions between the Val66Met polymorphism and antidepressant drug classes (multivariate models adjusted for propensity-scores: p=0.02 and p=0.03 respectively). With SSRI, Val/Val patients had a higher response rate 3 months post-treatment than Met patients (68.1% versus 44%; adjusted-OR: 3.04, IC95% [1.05; 9.37], p=0.04). With SNRI/TCA, Val/Val patients had a lower remission rate 6 months post-treatment than Met patients (33.3% versus 60.9%, adjusted-OR: 0.27, IC95% [0.09; 0.76], p=0.02). LIMITATIONS Limited sample size. CONCLUSIONS This study argues for a personalized prescription of antidepressants in Caucasian patients with major depressive disorder, based on the BDNF Val66Met polymorphism: SSRI should be preferred for Val/Val patients and SNRI/TCA for Met patients. Further studies are required to confirm these data.
Collapse
Affiliation(s)
- Romain Colle
- INSERM U1178 Team «Depression and Antidepressants», Faculté de Médecine Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France.
| | - Florence Gressier
- INSERM U1178 Team «Depression and Antidepressants», Faculté de Médecine Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France
| | - Céline Verstuyft
- INSERM U1184 «Immunologie des maladies virales et auto-immunes» Univ Paris Sud, Service de Génétique moléculaire, Pharmacogénétique et Hormonologie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre F-94275, France; Univ Paris-Sud, INSERM U1184, 92296 Chatenay-Malabry Cedex, France
| | - Eric Deflesselle
- INSERM U1178 Team «Depression and Antidepressants», Faculté de Médecine Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France
| | - Jean-Pierre Lépine
- Université Paris Diderot, Hôpital Saint-Louis Lariboisière Fernand Widal, Assistance Publique Hôpitaux de Paris, INSERM UMR-S1144, 200 rue du Faubourg Saint Denis, F-75475 Paris Cedex 10, France
| | - Florian Ferreri
- UPMC Univ Paris 06, Service de Psychiatrie, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - Patrick Hardy
- INSERM U1178 Team «Depression and Antidepressants», Faculté de Médecine Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France
| | - Jean-Philippe Guilloux
- INSERM U1178 Team «Depression and Antidepressants», Faculté de Pharmacie Paris Sud, Châtenay-Malabry, France
| | - Anne-Cécile Petit
- INSERM U1178 Team «Depression and Antidepressants», Faculté de Médecine Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France
| | - Bruno Fève
- INSERM UMR S938, UPMC Univ Paris 06, Centre de Recherche Saint-Antoine, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, 184 rue du Faubourg Saint-Antoine, F75012 Paris, France
| | - Bruno Falissard
- INSERM UMR 1178, Faculté de Médecine Paris Sud, Département de Biostatistiques, Hôpital Paul Brousse, Assistance Publique Hôpitaux de Paris, 94400 Villejuif, France
| | - Laurent Becquemont
- INSERM U1184 «Immunologie des maladies virales et auto-immunes» Univ Paris Sud, Service de Génétique moléculaire, Pharmacogénétique et Hormonologie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre F-94275, France; Univ Paris-Sud, INSERM U1184, 92296 Chatenay-Malabry Cedex, France
| | - Emmanuelle Corruble
- INSERM U1178 Team «Depression and Antidepressants», Faculté de Médecine Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France
| |
Collapse
|
18
|
Petit AC, Quesseveur G, Gressier F, Colle R, David DJ, Gardier AM, Ferreri F, Lépine JP, Falissard B, Verstuyft C, Guiard BP, Corruble E. Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2014; 54:76-82. [PMID: 24801750 DOI: 10.1016/j.pnpbp.2014.04.013] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Revised: 04/12/2014] [Accepted: 04/24/2014] [Indexed: 01/23/2023]
Abstract
An association between serotonin 2A receptor (5-HT2AR), encoded by HTR2A gene, and major depressive disorder (MDD) has been suggested. Here, we combined preclinical and ecological clinical approaches to explore the impact of impaired 5-HT2AR-mediated transmission on MDD or anxio-depressive-like phenotype in mice. Htr2a knock-out mice (Htr2a(-/-)) and wild-type mice were compared for the ability of chronic corticosterone to elicit some anxio-depressive-like phenotype in three behavioral paradigms (elevated plus maze, tail suspension test and splash test). Accordingly, two single nucleotide polymorphisms of the HTR2A gene (rs6314 ie His452Tyr and rs6313 ie 102C/T), which specific allelic variants may decrease 5-HT2AR-mediated transmission (as in Htr2a(-/-)mice), were studied in a sample of 485 Caucasian patients with MDD. In response to chronic corticosterone exposure, Htr2a(-/-) mice displayed more pronounced anxiodepressive-like phenotype than wild-type mice, as shown by a significant higher "emotionality score" (p<0.01). In patients, the C allele of rs6313 was more frequent in depressed patients (p=0.019) and was also associated with a more severe major depressive episode (p=0.03). This translational and ecological study involving constitutive Htr2a(-/-) knock-out mice and related SNPs in depressed patients suggests that a lower neurotransmission at the 5-HT2AR may favor the susceptibility and severity of MDE. It also suggests that specific allelic variants of the rs6313 and rs6314 may reduce 5-HT2AR-mediated transmission.
Collapse
Affiliation(s)
- Anne-Cécile Petit
- Université Paris Sud XI, INSERM U669, Département de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France.
| | - Gaël Quesseveur
- Université Paris Sud XI, Laboratoire de Neuropharmacologie EA 3544, Faculté de Pharmacie, Châtenay-Malabry Cedex, France
| | - Florence Gressier
- Université Paris Sud XI, INSERM U669, Département de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France
| | - Romain Colle
- Université Paris Sud XI, INSERM U669, Département de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France
| | - Denis J David
- Université Paris Sud XI, Laboratoire de Neuropharmacologie EA 3544, Faculté de Pharmacie, Châtenay-Malabry Cedex, France
| | - Alain M Gardier
- Université Paris Sud XI, Laboratoire de Neuropharmacologie EA 3544, Faculté de Pharmacie, Châtenay-Malabry Cedex, France
| | - Florian Ferreri
- Département de Psychiatrie, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - Jean-Pierre Lépine
- Hôpital Saint-Louis Lariboisière Fernand Widal, Assistance Publique Hôpitaux de Paris, INSERM U705, CNRS UMR8206, 200 rue du Faubourg Saint Denis, F-75475 Paris Cedex 10, France
| | - Bruno Falissard
- Université Paris Sud XI, INSERM U669, Département de Biostatistiques, Hôpital Paul Brousse, Assistance Publique Hôpitaux de Paris, 94400 Villejuif, France
| | - Céline Verstuyft
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service de Génétique moléculaire, Pharmacogénétique et Hormonologie, F-94275 Le Kremlin Bicêtre, France; Université Paris Sud XI, EA4123, F-92296 Châtenay-Malabry Cedex, France
| | - Bruno P Guiard
- Université Paris Sud XI, Laboratoire de Neuropharmacologie EA 3544, Faculté de Pharmacie, Châtenay-Malabry Cedex, France.
| | - Emmanuelle Corruble
- Université Paris Sud XI, INSERM U669, Département de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, 94275 Le Kremlin Bicêtre, France
| |
Collapse
|
19
|
Icick R, Peoc'h K, Ksouda K, Bloch V, Laplanche JL, Lépine JP, Bellivier F, Vorspan F. OPRM1 polymorphism and lifetime suicide attempts among stabilized, methadone-maintained outpatients. Psychiatry Res 2014; 218:259-60. [PMID: 24813900 DOI: 10.1016/j.psychres.2014.04.035] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 02/21/2014] [Accepted: 04/13/2014] [Indexed: 10/25/2022]
Affiliation(s)
- R Icick
- CSAPA "Espace Murger", Service de Psychiatrie d'Adultes, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France.
| | - K Peoc'h
- Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France; Service de Biochimie et de Biologie moléculaire, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, AP-HP, Paris, France
| | - K Ksouda
- Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France
| | - V Bloch
- Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France; Pharmacie hospitalière, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, AP-HP, Paris, France
| | - J L Laplanche
- Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France; Service de Biochimie et de Biologie moléculaire, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, AP-HP, Paris, France
| | - J P Lépine
- CSAPA "Espace Murger", Service de Psychiatrie d'Adultes, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France
| | - F Bellivier
- CSAPA "Espace Murger", Service de Psychiatrie d'Adultes, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France
| | - F Vorspan
- CSAPA "Espace Murger", Service de Psychiatrie d'Adultes, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France
| |
Collapse
|
20
|
Hajj A, Ksouda K, Peoc'h K, Curis E, Messali A, Deveaux LL, Bloch V, Prince N, Mouly S, Scherrmann JM, Lépine JP, Laplanche JL, Drici MD, Vorspan F. KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug Alcohol Depend 2014; 141:34-8. [PMID: 24875677 DOI: 10.1016/j.drugalcdep.2014.04.027] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Revised: 04/25/2014] [Accepted: 04/28/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND Many drugs increase the duration of the QT interval of patients, potentially leading to harmful effects such as polymorphic ventricular arrhythmias. Most of these drugs do so by inhibiting the rapid component IKr of the delayed rectifier potassium current IK. Methadone is the most prescribed heroin maintenance treatment and is known to inhibit the cardiac potassium channel hERG, which recapitulates IKr. In order to evaluate if any polymorphism of potassium channels' genes could explain some of the "idiosyncratic" QT prolongations observed in patients treated with methadone, we tested the association between KCNE1, KCNE2, and KCNH2 polymorphism and the QT interval prolongation in those patients, controlling for other variables associated with a decrease of the repolarizing reserve. METHODS A cohort of 82 patients treated with stable dosage of methadone (mean dosage 65 mg/d) for at least three months was genotyped for five polymorphisms in KCNE1, KCNE2 and KCNH2 genes and had their corrected QT (QTc) assessed. RESULTS The mean QTc interval was 415±34ms. In a linear regression model, longer QTc interval was associated with methadone dosage and with one genetic factor. Each copy of a Lys allele at codon 897 of KCNH2, the gene that encodes the cardiac potassium voltage-gated channel hERG, was associated with a 15.4ms longer QTc (95% CI [4.6-26.2]; p=0.001). CONCLUSION KCNH2 genotyping may be relevant in the analysis of cumulative risk factors for QT prolongation in patients on methadone maintenance treatment.
Collapse
Affiliation(s)
- Aline Hajj
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France; AP-HP, Hôpital Lariboisière, Service de Biochimie et Biologie moléculaire, 2 rue Ambroise Paré, 75010 Paris, France; Pharmacology Unit, Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, Saint Joseph University, Beirut, Lebanon
| | - Kamilia Ksouda
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France; AP-HP, Hôpital Fernand Widal, Service de Psychiatrie, 200 rue du Fg St Denis, 75010 Paris, France
| | - Katell Peoc'h
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France; AP-HP, Hôpital Lariboisière, Service de Biochimie et Biologie moléculaire, 2 rue Ambroise Paré, 75010 Paris, France
| | - Emmanuel Curis
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France; Université Paris Descartes, Faculté de Pharmacie, Département de Biostatistiques, 4 avenue de l'Observatoire, 75006 Paris, France
| | - Anne Messali
- AP-HP, Hôpital Lariboisière, Service de Cardiologie, 2 rue Ambroise Paré, 75010 Paris, France
| | - Laurence Labat Deveaux
- AP-HP, Hôtel Dieu Service de Pharmacie - Pharmacologie - Toxicologie, 1 place du Parvis Notre Dame, 75004 Paris, France
| | - Vanessa Bloch
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France
| | - Nathalie Prince
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France
| | - Stéphane Mouly
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France
| | - Jean-Michel Scherrmann
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France
| | - Jean-Pierre Lépine
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France; AP-HP, Hôpital Fernand Widal, Service de Psychiatrie, 200 rue du Fg St Denis, 75010 Paris, France
| | - Jean-Louis Laplanche
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France; AP-HP, Hôpital Lariboisière, Service de Biochimie et Biologie moléculaire, 2 rue Ambroise Paré, 75010 Paris, France
| | | | - Florence Vorspan
- INSERM UMR-S 1144, Variabilité de la Réponse aux Psychotropes, Université Paris Descartes, Université Paris Diderot, PRES Sorbonne Paris Cité, Hôpital Fernand Widal, 200 rue du Fg St Denis, 75010 Paris, France; AP-HP, Hôpital Fernand Widal, Service de Psychiatrie, 200 rue du Fg St Denis, 75010 Paris, France.
| |
Collapse
|
21
|
Dupuy G, Cavalcanti L, Bourgogne E, Brichant-Petitjean C, Gomberoff L, Bloch V, Bellivier F, Lépine JP, Laprévote O, Vorspan F. Are empty methadone bottles empty? An analytic study. Harm Reduct J 2014; 11:20. [PMID: 24990630 PMCID: PMC4094677 DOI: 10.1186/1477-7517-11-20] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 06/20/2014] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Methadone maintenance treatment is the most widely prescribed treatment for opiate dependence with proven benefits for patients. In naïve users or in case of recreational misuse, methadone can be a source of potentially lethal intoxications, resulting in fatal overdoses. A few cases of infantile intoxications have been described in the literature, some of which resulted in death. Nowadays, more than 50,000 bottles are used every day in France, most of which are thrown away in the bin. Relatives at home, especially children, can have access to these empty bottles. This study aims to determine whether the residual quantity of methadone in the bottles is associated with a risk of intoxication for someone who has a low tolerance to opiates, such as a child. METHODS The methadone dosage left in a sample of 175 bottles recapped after use by the patients taking their maintenance treatment in an addiction treatment program centre was analysed during a 2-week period in March 2013. RESULTS The mean residual quantity of methadone left in each bottle after use is 1.9 ± 1.8 mg and 3.3 ± 2.4 mg in the sample of 60 mg bottles. CONCLUSIONS There is a potential danger of accidental overdose with empty bottles of methadone syrup, especially for children. To take into account this hazard, several harm reduction strategies can be proposed, such as favouring the taking of the treatment within the delivery centres rather than the 'take home' doses, asking methadone users to bring back their used bottles, and raising patients' awareness of the intoxication risks and the necessary everyday precautions. For stable patients with take home methadone, the use of capsules could be considered.
Collapse
Affiliation(s)
- Gaël Dupuy
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Psychiatrie, Hôpital Fernand-Widal, 200, rue du Faubourg St-Denis, Paris 75010, France
- Unité Variabilité de Réponse aux Psychotropes, Inserm U1144, Universités Paris-Descartes et Paris Diderot, PRES Sorbonne Paris Cité, 4, Avenue de l’Observatoire, Paris 75006, France
| | - Lia Cavalcanti
- Aurore, Association EGO, 6 rue de Clignancourt, Paris 75018, France
| | - Emmanuel Bourgogne
- AP-HP, Hôpital Lariboisière, Service de Toxicologie Biologique et Pharmacologie, 2 rue Ambroise Paré, Paris 75010, France
- Laboratoire de Chimie, Toxicologie Analytique et Cellulaire, CNRS UMR 8638 COMETE, Faculté de Pharmacie, Université Paris-Descartes, PRES Sorbonne Paris Cité, 4, Avenue de l’Observatoire, Paris 75006, France
| | - Clara Brichant-Petitjean
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Psychiatrie, Hôpital Fernand-Widal, 200, rue du Faubourg St-Denis, Paris 75010, France
- Unité Variabilité de Réponse aux Psychotropes, Inserm U1144, Universités Paris-Descartes et Paris Diderot, PRES Sorbonne Paris Cité, 4, Avenue de l’Observatoire, Paris 75006, France
| | - Léon Gomberoff
- Aurore, Association EGO, 6 rue de Clignancourt, Paris 75018, France
| | - Vanessa Bloch
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Psychiatrie, Hôpital Fernand-Widal, 200, rue du Faubourg St-Denis, Paris 75010, France
- Unité Variabilité de Réponse aux Psychotropes, Inserm U1144, Universités Paris-Descartes et Paris Diderot, PRES Sorbonne Paris Cité, 4, Avenue de l’Observatoire, Paris 75006, France
| | - Frank Bellivier
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Psychiatrie, Hôpital Fernand-Widal, 200, rue du Faubourg St-Denis, Paris 75010, France
- Unité Variabilité de Réponse aux Psychotropes, Inserm U1144, Universités Paris-Descartes et Paris Diderot, PRES Sorbonne Paris Cité, 4, Avenue de l’Observatoire, Paris 75006, France
| | - Jean-Pierre Lépine
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Psychiatrie, Hôpital Fernand-Widal, 200, rue du Faubourg St-Denis, Paris 75010, France
- Unité Variabilité de Réponse aux Psychotropes, Inserm U1144, Universités Paris-Descartes et Paris Diderot, PRES Sorbonne Paris Cité, 4, Avenue de l’Observatoire, Paris 75006, France
| | - Olivier Laprévote
- AP-HP, Hôpital Lariboisière, Service de Toxicologie Biologique et Pharmacologie, 2 rue Ambroise Paré, Paris 75010, France
- Laboratoire de Chimie, Toxicologie Analytique et Cellulaire, CNRS UMR 8638 COMETE, Faculté de Pharmacie, Université Paris-Descartes, PRES Sorbonne Paris Cité, 4, Avenue de l’Observatoire, Paris 75006, France
| | - Florence Vorspan
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Psychiatrie, Hôpital Fernand-Widal, 200, rue du Faubourg St-Denis, Paris 75010, France
- Unité Variabilité de Réponse aux Psychotropes, Inserm U1144, Universités Paris-Descartes et Paris Diderot, PRES Sorbonne Paris Cité, 4, Avenue de l’Observatoire, Paris 75006, France
| |
Collapse
|
22
|
Icick R, Millet É, Curis E, Bellivier F, Lépine JP. Predictive value of baseline resistance in early response to antidepressants. J Affect Disord 2014; 161:127-35. [PMID: 24751320 DOI: 10.1016/j.jad.2014.03.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Revised: 03/02/2014] [Accepted: 03/03/2014] [Indexed: 11/28/2022]
Abstract
BACKGROUND Major Depressive Disorder (MDD) is the 3rd source for burden worldwide according to the World Health Organization (WHO). This comes partly from unsatisfactory response rates after usual treatment, highlighting the need for early indicators such as early improvement of depressive symptoms to adapt treatment strategies, especially for severe inpatients. Thus our objective was to assess the predictive value of baseline partial resistance in early antidepressant response (EAR), hypothesizing that previous treatment failures would decrease the probability of early response. METHODS We included 122 consecutive inpatients with current unipolar MDE. The Mini-Neuropsychiatric Interview was used to ascertain DSM-IV diagnoses of MDD as well as psychiatric comorbidities, and to exclude patients with a history of bipolar disorder. A specifically designed questionnaire was used to collect data on previous treatment trials for the current episode so as to generate scores on the five existing methods for quantifying treatment resistance. We prospectively assessed EAR, defined as a 50% decrease in MADRS after 14 days of steady regimen of antidepressant. RESULTS In the per protocol sample (N=76), multivariate analyses showed that psychotic features at baseline remained an independent predictor of absence of EAR (p<.01), unlike baseline partial resistance, which may rather be associated with a lack of any improvement. LIMITATIONS Lack of data about further response and non-randomized treatment allocation. CONCLUSION Available methods for quantifying treatment resistance are heterogeneous and do not predict short-term response among severely depressed inpatients, despite potential usefulness in predicting a lack of early improvement.
Collapse
Affiliation(s)
- Romain Icick
- Service de Psychiatrie d׳Adultes du Pr F. Bellivier, AP-HP, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France; Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France.
| | | | - Emmanuel Curis
- Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France
| | - Frank Bellivier
- Service de Psychiatrie d׳Adultes du Pr F. Bellivier, AP-HP, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France; Fondation FondaMental, Hôpital Albert Chenevier, AP-HP, Créteil, France; Inserm U955 - Équipe 15, Université Paris Est, Faculté de Médecine, Créteil, France
| | - Jean-Pierre Lépine
- Service de Psychiatrie d׳Adultes du Pr F. Bellivier, AP-HP, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Paris, France; Inserm UMR-S 1144, Universités Paris Descartes - Paris Diderot, Paris, France; Fondation FondaMental, Hôpital Albert Chenevier, AP-HP, Créteil, France
| |
Collapse
|
23
|
O'Neill S, Posada-Villa J, Medina-Mora ME, Al-Hamzawi AO, Piazza M, Tachimori H, Hu C, Lim C, Bruffaerts R, Lépine JP, Matschinger H, de Girolamo G, de Jonge P, Alonso J, Caldas-de-Almeida JM, Florescu S, Kiejna A, Levinson D, Kessler RC, Scott KM. Associations between DSM-IV mental disorders and subsequent self-reported diagnosis of cancer. J Psychosom Res 2014; 76:207-12. [PMID: 24529039 PMCID: PMC5129659 DOI: 10.1016/j.jpsychores.2013.12.012] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2013] [Revised: 12/21/2013] [Accepted: 12/31/2013] [Indexed: 10/25/2022]
Abstract
OBJECTIVE The associations between mental disorders and cancer remain unclear. It is also unknown whether any associations vary according to life stage or gender. This paper examines these research questions using data from the World Mental Health Survey Initiative. METHODS The World Health Organization Composite International Diagnostic Interview retrospectively assessed the lifetime prevalence of 16 DSM-IV mental disorders in face-to-face household population surveys in nineteen countries (n = 52,095). Cancer was indicated by self-report of diagnosis. Smoking was assessed in questions about current and past tobacco use. Survival analyses estimated associations between first onset of mental disorders and subsequently reported cancer. RESULTS After adjustment for comorbidity, panic disorder, specific phobia and alcohol abuse were associated with a subsequently self-reported diagnosis of cancer. There was an association between number of mental disorders and the likelihood of reporting a cancer diagnosis following the onset of the mental disorder. This suggests that the associations between mental disorders and cancer risk may be generalised, rather than specific to a particular disorder. Depression is more strongly associated with self-reported cancers diagnosed early in life and in women. PTSD is also associated with cancers diagnosed early in life. CONCLUSION This study reports the magnitude of the associations between mental disorders and a self-reported diagnosis of cancer and provides information about the relevance of comorbidity, gender and the impact at different stages of life. The findings point to a link between the two conditions and lend support to arguments for early identification and treatment of mental disorders.
Collapse
Affiliation(s)
- Siobhan O'Neill
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom.
| | - Jose Posada-Villa
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Maria Elena Medina-Mora
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Ali Obaid Al-Hamzawi
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Marina Piazza
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Hisateru Tachimori
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Chiyi Hu
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Carmen Lim
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Ronny Bruffaerts
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Jean-Pierre Lépine
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Herbert Matschinger
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Giovanni de Girolamo
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Peter de Jonge
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Jordi Alonso
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Jose Miguel Caldas-de-Almeida
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Silvia Florescu
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Andrzej Kiejna
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Daphna Levinson
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Ronald C Kessler
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| | - Kate M Scott
- Bamford Centre for Mental Health and Well-Being, University of Ulster, Londonderry, Northern Ireland, United Kingdom
| |
Collapse
|
24
|
Viana MC, Gruber MJ, Shahly V, Alhamzawi A, Alonso J, Andrade LH, Angermeyer MC, Benjet C, Bruffaerts R, Caldas-de-Almeida JM, Girolamo GD, Jonge PD, Ferry F, Florescu S, Gureje O, Haro JM, Hinkov H, Hu C, Karam EG, Lépine JP, Levinson D, Posada-Villa J, Sampson NA, Kessler RC. Family burden related to mental and physical disorders in the world: results from the WHO World Mental Health (WMH) surveys. Braz J Psychiatry 2014; 35:115-25. [PMID: 23904015 DOI: 10.1590/1516-4446-2012-0919] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Accepted: 08/08/2012] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To assess prevalence and correlates of family caregiver burdens associated with mental and physical conditions worldwide. METHODS Cross-sectional community surveys asked 43,732 adults residing in 19 countries of the WHO World Mental Health (WMH) Surveys about chronic physical and mental health conditions of first-degree relatives and associated objective (time, financial) and subjective (distress, embarrassment) burdens. Magnitudes and associations of burden are examined by kinship status and family health problem; population-level estimates are provided. RESULTS Among the 18.9-40.3% of respondents in high, upper-middle, and low/lower-middle income countries with first-degree relatives having serious health problems, 39.0-39.6% reported burden. Among those, 22.9-31.1% devoted time, 10.6-18.8% had financial burden, 23.3-27.1% reported psychological distress, and 6.0-17.2% embarrassment. Mean caregiving hours/week was 12.9-16.5 (83.7-147.9 hours/week/100 people aged 18+). Mean financial burden was 15.1% of median family income in high, 32.2% in upper-middle, and 44.1% in low/lower-middle income countries. A higher burden was reported by women than men, and for care of parents, spouses, and children than siblings. CONCLUSIONS The uncompensated labor of family caregivers is associated with substantial objective and subjective burden worldwide. Given the growing public health importance of the family caregiving system, it is vital to develop effective interventions that support family caregivers.
Collapse
Affiliation(s)
- Maria Carmen Viana
- Department of Social Medicine, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Icick R, Lauer S, Romo L, Dupuy G, Lépine JP, Vorspan F. Dysfunctional parental styles perceived during childhood in outpatients with substance use disorders. Psychiatry Res 2013; 210:522-8. [PMID: 23880480 DOI: 10.1016/j.psychres.2013.06.041] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/06/2012] [Revised: 04/11/2013] [Accepted: 06/22/2013] [Indexed: 11/16/2022]
Abstract
People who suffer from substance use disorders (SUDs) frequently report to have undergone childhood adversity that is often associated with father or mother dysfunction, or both. Yet that issue has been barely addressed in opiate dependent patients. Therefore we sought to evaluate parent-specific dysfunctional styles perceived during childhood in a clinical sample from an outpatient addiction treatment program using the Measure Of Parental Styles (MOPS) questionnaire. DSM-IV diagnoses of substance use disorders and history of suicide attempts, family structure and changes of caregiver during childhood were obtained from 159 consecutive outpatients, along with their perception of parental bonding with the MOPS, in which mother and father scores are separate. Mother neglect dimension was significantly correlated with an earlier age at onset of several substances' use, the number of prior hospitalizations and of lifetime suicide attempts. Most of these associations remained significant in multivariate models. This was the first assessment of a representative sample of outpatients with SUDs by the MOPS questionnaire. Given its excellent acceptance and its association with several key correlates of SUDs, it should be used to design specific interventions targeted at attachment and familial management as well as in research models on gene × environment interactions.
Collapse
Affiliation(s)
- Romain Icick
- CSAPA Espace Murger, Service de Psychiatrie d'Adultes du Pr F Bellivier, Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris, France; INSERM U 705, CNRS UMR 8206, Paris, France.
| | | | | | | | | | | |
Collapse
|
26
|
Glantz MD, Medina-Mora ME, Petukhova M, Andrade LH, Anthony JC, de Girolamo G, de Graaf R, Degenhardt L, Demyttenaere K, Florescu S, Gureje O, Haro JM, Horiguchi I, Karam EG, Kostyuchenko S, Lee S, Lépine JP, Matschinger H, Neumark Y, Posada-Villa J, Sagar R, Stein DJ, Tomov T, Wells JE, Chatterji S, Kessler RC. Alcohol abuse in developed and developing countries in the World Mental Health Surveys: Socially defined consequences or psychiatric disorder? Am J Addict 2013; 23:145-55. [PMID: 25187050 DOI: 10.1111/j.1521-0391.2013.12082.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2012] [Revised: 03/05/2013] [Accepted: 03/23/2013] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Previous single country research has raised concerns that: (1) the DSM-IV diagnosis of alcohol abuse (AA) is met primarily through the hazardous use criterion related to drinking and driving and (2) that the hazardous use and social consequences AA criteria primarily reflect varying socioeconomic and cultural factors rather than psychiatric disorder. METHODS Using representative cross-national data from the 21 countries in the World Mental Health surveys, adults meeting DSM-IV lifetime criteria for AA but not dependence from 10 developed (n=46,071) and 11 developing (n=49,761) countries were assessed as meeting AA with the hazardous use or the social consequences criteria. RESULTS Between 29.3% (developed) and 16.2% (developing) of respondents with AA met only the hazardous use criterion. AA cases with and without hazardous use were similar in age-of-onset, course, predictors, and psychopathological consequences in both developed and developing countries. DISCUSSION AND CONCLUSIONS Despite some associations of the AA criteria with socioeconomic factors, the hazardous use and social consequences criteria were significantly associated with psychiatric predictors and sequelae. The findings indicate that these criteria reflect psychiatric disorder and are appropriate for inclusion as DSM-5 Alcohol Use Disorder criteria. SCIENTIFIC SIGNIFICANCE These findings support a psychiatric rather than a sociocultural view of the hazardous use and social consequences symptoms and provide evidence that they are appropriate diagnostic criteria cross-nationally with utility in a wide range of socioeconomic environments. This suggests consideration for their adoption by ICD-11. Further research is needed on the implications of these results for prevention and treatment.
Collapse
Affiliation(s)
- Meyer D Glantz
- Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Scott KM, de Jonge P, Alonso J, Viana MC, Liu Z, O'Neill S, Aguilar-Gaxiola S, Bruffaerts R, Caldas-de-Almeida JM, Stein DJ, de Girolamo G, Florescu SE, Hu C, Taib NI, Lépine JP, Levinson D, Matschinger H, Medina-Mora ME, Piazza M, Posada-Villa JA, Uda H, Wojtyniak BJ, Lim CCW, Kessler RC. Associations between DSM-IV mental disorders and subsequent heart disease onset: beyond depression. Int J Cardiol 2013; 168:5293-9. [PMID: 23993321 DOI: 10.1016/j.ijcard.2013.08.012] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2013] [Revised: 07/25/2013] [Accepted: 08/03/2013] [Indexed: 11/29/2022]
Abstract
BACKGROUND Prior studies on the depression-heart disease association have not usually used diagnostic measures of depression, or taken other mental disorders into consideration. As a result, it is not clear whether the association between depression and heart disease onset reflects a specific association, or the comorbidity between depression and other mental disorders. Additionally, the relative magnitude of associations of a range of mental disorders with heart disease onset is unknown. METHODS Face-to-face household surveys were conducted in 19 countries (n=52,095; person years=2,141,194). The Composite International Diagnostic Interview retrospectively assessed lifetime prevalence and age at onset of 16 DSM-IV mental disorders. Heart disease was indicated by self-report of physician's diagnosis, or self-report of heart attack, together with their timing (year). Survival analyses estimated associations between first onset of mental disorders and subsequent heart disease onset. RESULTS After comorbidity adjustment, depression, panic disorder, specific phobia, post-traumatic stress disorder and alcohol use disorders were associated with heart disease onset (ORs 1.3-1.6). Increasing number of mental disorders was associated with heart disease in a dose-response fashion. Mood disorders and alcohol abuse were more strongly associated with earlier onset than later onset heart disease. Associations did not vary by gender. CONCLUSIONS Depression, anxiety and alcohol use disorders were significantly associated with heart disease onset; depression was the weakest predictor. If confirmed in future prospective studies, the breadth of psychopathology's links with heart disease onset has substantial clinical and public health implications.
Collapse
Affiliation(s)
- Kate M Scott
- Department of Psychological Medicine, University of Otago, Dunedin, New Zealand.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Kovess-Masfety V, Alonso J, Angermeyer M, Bromet E, de Girolamo G, de Jonge P, Demyttenaere K, Florescu SE, Gruber MJ, Gureje O, Hu C, Huang Y, Karam EG, Jin R, Lépine JP, Levinson D, McLaughlin KA, Medina-Mora ME, O’Neill S, Ono Y, Posada-Villa JA, Sampson NA, Scott KM, Shahly V, Stein DJ, Viana MC, Zarkov Z, Kessler RC. Irritable mood in adult major depressive disorder: results from the world mental health surveys. Depress Anxiety 2013; 30:395-406. [PMID: 23364997 PMCID: PMC4117370 DOI: 10.1002/da.22033] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Revised: 11/07/2012] [Accepted: 11/11/2012] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Although irritability is a core symptom of DSM-IV major depressive disorder (MDD) for youth but not adults, clinical studies find comparable rates of irritability between nonbipolar depressed adults and youth. Including irritability as a core symptom of adult MDD would allow detection of depression-equivalent syndromes with primary irritability hypothesized to be more common among males than females. We carried out a preliminary examination of this issue using cross-national community-based survey data from 21 countries in the World Mental Health (WMH) Surveys (n = 110,729). METHODS The assessment of MDD in the WHO Composite International Diagnostic Interview includes one question about persistent irritability. We examined two expansions of the definition of MDD involving this question: (1) cases with dysphoria and/or anhedonia and exactly four of nine Criterion A symptoms plus irritability; and (2) cases with two or more weeks of irritability plus four or more other Criterion A MDD symptoms in the absence of dysphoria or anhedonia. RESULTS Adding irritability as a tenth Criterion A symptom increased lifetime prevalence by 0.4% (from 11.2 to 11.6%). Adding episodes of persistent irritability increased prevalence by an additional 0.2%. Proportional prevalence increases were significantly higher, but nonetheless small, among males compared to females. Rates of severe role impairment were significantly lower among respondents with this irritable depression who did not meet conventional DSM-IV criteria than those with DSM-IV MDD. CONCLUSION Although limited by the superficial assessment in this single question on irritability, results do not support expanding adult MDD criteria to include irritable mood.
Collapse
Affiliation(s)
- Viviane Kovess-Masfety
- Université Paris Descartes & EHESP School for Public Health Department of Epidemiology, Paris, France.
| | - Jordi Alonso
- Health Services Research Unit, IMIM (Hospital del Mar Research Institute), and CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | | | - Evelyn Bromet
- Department of Psychiatry, State University of New York at Stony Brook, Stony Brook, New York
| | | | - Peter de Jonge
- University Medical Center Groningen, Groningen, The Netherlands
| | - Koen Demyttenaere
- Department of Psychiatry, University Hospital Gasthuisberg, University Hospital, Leuven, Belgium
| | - Silvia E. Florescu
- Public Health Research and Evidence Based Medicine Department, National School of Public Health and Health Services Management, Bucharest, Romania
| | - Michael J. Gruber
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
| | - Oye Gureje
- Department of Psychiatry, University College Hospital, Ibadan, Nigeria
| | - Chiyi Hu
- Shenzhen Institute of Mental Health & Shenzhen Kangning Hospital, Shenzhen, People’s Republic of China
| | - Yueqin Huang
- Institute of Mental Health, Peking University, Beijing, China
| | - Elie G. Karam
- Department of Psychiatry and Clinical Psychology Institute for Development, Research, Advocacy, and Applied Care (IDRAAC), St. George Hospital University Medical Center, Beirut, Lebanon
| | - Robert Jin
- Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts
| | | | - Daphna Levinson
- Mental Health Services, Ministry of Health, Jerusalem, Israel
| | - Katie A. McLaughlin
- Division of General Pediatrics, Children’s Hospital Boston and Harvard Medical School, Boston, Massachusetts
| | | | - Siobhan O’Neill
- School of Psychology, University of Ulster, Londonderry, United Kingdom
| | - Yutaka Ono
- National Center for Neurology and Psychiatry, Center for Cognitive Behavior Therapy and Research, Tokyo, Japan
| | | | - Nancy A. Sampson
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
| | - Kate M. Scott
- Department of Psychological Medicine, Otago University, Dunedin, New Zealand
| | - Victoria Shahly
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
| | - Dan J. Stein
- Department of Psychiatry, University of Cape Town, South Africa
| | - Maria C. Viana
- Department of Social Medicine, Federal University of Espírito Santo (UFES), Vitória, Espírito Santo, Brazil
| | - Zahari Zarkov
- National Center of Public Health and Analyses, Department Mental Health, Sofia, Bulgaria
| | - Ronald C. Kessler
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
29
|
Vorspan F, Brousse G, Bloch V, Bellais L, Romo L, Guillem E, Coeuru P, Lépine JP. Cocaine-induced psychotic symptoms in French cocaine addicts. Psychiatry Res 2012; 200:1074-6. [PMID: 22551940 DOI: 10.1016/j.psychres.2012.04.008] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2010] [Revised: 03/14/2012] [Accepted: 04/02/2012] [Indexed: 11/16/2022]
Abstract
Cocaine use is known to induce transient psychotic symptoms. We evaluated retrospectively the lifetime prevalence of cocaine-induced psychotic symptoms in 105 cocaine addicts with the French version of the Scale for Assessment of Positive Symptoms-Cocaine Induced Psychosis (SAPS-CIP) in a clinical setting. Most patients (86.5%) described such symptoms.
Collapse
Affiliation(s)
- Florence Vorspan
- Service de Psychiatrie, et Neuropsychopharmacologie des Addictions, INSERM U705, UMR 8206, PRES-Sorbonne Paris-Cité, Hôpital Fernand Widal, AP-HP, 200 rue du Faubourg Saint Denis, F-75010 Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Vorspan F, Bertoux M, Brichant-Petitjean C, Dubois B, Lépine JP. Relapsing-remitting behavioural variant of frontotemporal dementia in a bipolar patient. Funct Neurol 2012; 27:193-196. [PMID: 23402681 PMCID: PMC3812761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
We report the case of a bipolar I patient who was diagnosed with frontotemporal dementia at the age of 54 during a manic episode. Her neurological state improved when this episode ended. Each subsequent thymic relapse was associated with cognitive deficits which subsided when the patient became euthymic, even though SPECT continued to show the same frontal hypoperfusion. We here discuss the hypothesis that the cognitive reserve of this patient, a former journalist, may, except during her mood episodes, have provided her with sufficient resources to meet her life demands despite her underlying neurological disorder.
Collapse
Affiliation(s)
- Florence Vorspan
- Psychiatry Department, Fernand Widal Hospital, Assistance Publique - Hôpitaux de Paris, France.
| | | | | | | | | |
Collapse
|
31
|
Vorspan F, Bellais L, Romo L, Bloch V, Neira R, Lépine JP. The Obsessive-Compulsive Cocaine Scale (OCCS): a pilot study of a new questionnaire for assessing cocaine craving. Am J Addict 2012; 21:313-9. [PMID: 22691009 DOI: 10.1111/j.1521-0391.2012.00248.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
This study aimed to develop a scale (Obsessive-Compulsive Cocaine Scale [OCCS]) for measuring cocaine craving based on the Obsessive Compulsive Drinking Scale (OCDS). We tested the scale on 116 French-speaking cocaine users. The scale was reliable (Cronbach's α= 0.93). It was significantly correlated with a visual analogue scale of craving (r = 0.641, p < .001) and discriminated between cocaine-dependant subjects (score 36 ± 11) and abusers (score 17 ± 9, p < .001). Prospective tests on a sample of 20 subjects showed that the OCCS score changed over 3 weeks of treatment and was significantly correlated with the visual analogue scale of craving (r = 0.492, p = .038). Principal component analysis identified three factors: resistance, intensity, and interference. The OCCS questionnaire could be used to repeatedly assess cocaine craving in prospective studies in cocaine addicts. (Am J Addict 2012;00:1-7).
Collapse
Affiliation(s)
- Florence Vorspan
- Pôle Addictologie-Toxicologie-Psychiatrie, Hôpital Fernand Widal, AP-HP et Neuropsychopharmacologie des Addictions, Université PRES-Sorbonne-Paris-Cité, Paris, France.
| | | | | | | | | | | |
Collapse
|
32
|
Bertoux M, Delavest M, de Souza LC, Funkiewiez A, Lépine JP, Fossati P, Dubois B, Sarazin M. Social Cognition and Emotional Assessment differentiates frontotemporal dementia from depression. J Neurol Neurosurg Psychiatry 2012; 83:411-6. [PMID: 22291219 DOI: 10.1136/jnnp-2011-301849] [Citation(s) in RCA: 116] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Behavioural variant of frontotemporal dementia (bvFTD) is a neurodegenerative disease that is clinically characterised by progressive behavioural changes and social interpersonal dysfunctions. Its diagnosis remains a clinical challenge, and depression is one of the main causes of misdiagnoses due to the prevalence of apathy in bvFTD. OBJECTIVE To evaluate the sensitivity and specificity of the Social Cognition and Emotional Assessment (SEA) and the mini-SEA for differentiating bvFTD from major depressive disorder (MDD). METHODS Scores for the SEA and mini-SEA for 37 patients with bvFTD (divided into subgroups of 17 with early bvFTD and 20 with moderate bvFTD according to the normal range of the Mattis Dementia Rating Scale), 19 MDD patients and 30 control subjects were compared to define the discrimination power of these tools compared with other standard neuropsychological tests. RESULTS SEA and mini-SEA scores were significantly lower for both the early and moderate bvFTD groups compared with control subjects and the MDD group, and very few scores overlapped between patients in the bvFTD subgroups and patients in the MDD and control subgroups. SEA and mini-SEA scores distinguished early bvFTD from MDD with sensitivity and specificity rates above 94%. CONCLUSION Unlike standard executive neuropsychological tests, SEA and the mini-SEA can differentiate MDD from bvFTD in the early stages of the disease. The mini-SEA is an easy tool that can be utilised in neurological or psychiatric departments.
Collapse
Affiliation(s)
- Maxime Bertoux
- Université Pierre et Marie-Curie(UPMC) - Paris 6, Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Guillem E, Notides C, Debray M, Vorspan F, Musa C, Leroux M, Nieto I, Lépine JP. Psychometric Properties of the Cannabis Use Disorders Identification Test in French Cannabis Misusers. J Addict Nurs 2011. [DOI: 10.3109/10884602.2011.616604] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
34
|
Sarrazin S, Etain B, Vederine FE, d'Albis MA, Hamdani N, Daban C, Delavest M, Lépine JP, Leboyer M, Mangin JF, Poupon C, Houenou J. MRI exploration of pineal volume in bipolar disorder. J Affect Disord 2011; 135:377-9. [PMID: 21700342 DOI: 10.1016/j.jad.2011.06.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2011] [Revised: 05/31/2011] [Accepted: 06/01/2011] [Indexed: 11/30/2022]
Abstract
BACKGROUND Circadian rhythm instability and abnormalities of melatonin secretion are considered as trait markers of bipolar disorder. Melatonin is secreted by the pineal gland. We investigated pineal volume in patients with bipolar disorder, and expected to observe smaller than normal pineal glands in cases of bipolar disorder. METHODS The primary outcome was the total pineal volume measured for each pineal gland with T1 MRI sequence. Twenty patients with bipolar I and II disorder and twenty controls were recruited. Pineal glands with large cysts (type 3) were excluded. RESULTS After exclusion of individuals with type 3 cysts, 32 subjects were analyzed for total pineal volume (16 patients with bipolar disorder and 16 controls). Total pineal volume did not differ significantly between patients (total pineal volume=115+/-54.3mm(3)) and controls (total pineal volume=110+/-40.5mm(3)). CONCLUSIONS Contrary to our hypothesis, no difference in total pineal volume between patients with bipolar disorder and healthy subjects was observed. These results indicate that the putative dysfunction of the pineal gland in bipolar disorder could be not directly related to an abnormal volume of the pineal gland.
Collapse
Affiliation(s)
- Samuel Sarrazin
- AP-HP, University Paris-East, Department of Psychiatry, Henri Mondor-Albert Chenevier Hospitals, Créteil, F-94010, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Vorspan F, Bloch V, Brousse G, Bellais L, Gascon J, Lépine JP. Prospective assessment of transient cocaine-induced psychotic symptoms in a clinical setting. Am J Addict 2011; 20:535-7. [PMID: 21999499 DOI: 10.1111/j.1521-0391.2011.00181.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Cocaine use is associated with the occurrence of transient psychotic symptoms. Sixteen poly-substance abusers already in treatment, who were diagnosed with crack dependence, were assessed twice: at baseline and after 3 weeks of medical management specifically aimed at cocaine abstinence. The psychotic symptoms were assessed with the French version of the Scale for Assessment of Positive Symptoms-Cocaine-Induced Psychosis (SAPS-CIP). There was a decrease of both cocaine intake and psychotic symptoms at week 3 (Wilcoxon's Z, p < .001 and .028, respectively). Furthermore, there was a significant correlation between psychotic symptoms and dose reduction (r(2) = .49, Spearman's ρ= .613, p < .012).
Collapse
Affiliation(s)
- Florence Vorspan
- Neuropsychopharmacologie des Addictions, INSERM U, CNRS UMR, Université PRES Sorbonne-Paris Cité, Paris, France.
| | | | | | | | | | | |
Collapse
|
36
|
Scott KM, Von Korff M, Angermeyer MC, Benjet C, Bruffaerts R, de Girolamo G, Haro JM, Lépine JP, Ormel J, Posada-Villa J, Tachimori H, Kessler RC. Association of childhood adversities and early-onset mental disorders with adult-onset chronic physical conditions. ACTA ACUST UNITED AC 2011; 68:838-44. [PMID: 21810647 DOI: 10.1001/archgenpsychiatry.2011.77] [Citation(s) in RCA: 224] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
CONTEXT The physical health consequences of childhood psychosocial adversities may be as substantial as the mental health consequences, but whether this is the case remains unclear because much prior research has involved unrepresentative samples and a selective focus on particular adversities or physical outcomes. The association between early-onset mental disorders and subsequent poor physical health in adulthood has not been investigated. OBJECTIVE To investigate whether childhood adversities and early-onset mental disorders are independently associated with increased risk of a range of adult-onset chronic physical conditions in culturally diverse samples spanning the full adult age range. DESIGN Cross-sectional community surveys of adults in 10 countries. SETTING General population. PARTICIPANTS Adults (ie, aged ≥18 years; N = 18 303), with diagnostic assessment and determination of age at onset of DSM-IV mental disorders, assessment of childhood familial adversities, and age of diagnosis or onset of chronic physical conditions. MAIN OUTCOME MEASURES Risk (ie, hazard ratios) of adult-onset (ie, at age >20 years) heart disease, asthma, diabetes mellitus, arthritis, chronic spinal pain, and chronic headache as a function of specific childhood adversities and early-onset (ie, at age <21 years) DSM-IV depressive and anxiety disorders, with mutual adjustment. RESULTS A history of 3 or more childhood adversities was independently associated with onset of all 6 physical conditions (hazard ratios, 1.44 to 2.19). Controlling for current mental disorder made little difference to these associations. Early-onset mental disorders were independently associated with onset of 5 physical conditions (hazard ratios, 1.43 to 1.66). CONCLUSIONS These results are consistent with the hypothesis that childhood adversities and early-onset mental disorders have independent, broad-spectrum effects that increase the risk of diverse chronic physical conditions in later life. They require confirmation in a prospectively designed study. The long course of these associations has theoretical and research implications.
Collapse
Affiliation(s)
- Kate M Scott
- Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Guillem E, Notides C, Vorspan F, Debray M, Nieto I, Leroux M, Lépine JP. Cannabis Expectancies in Substance Misusers: French Validation of the Marijuana Effect Expectancy Questionnaire. Am J Addict 2011; 20:543-54. [PMID: 21999501 DOI: 10.1111/j.1521-0391.2011.00171.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- Eric Guillem
- Groupe hospitalier Lariboisière-Fernand Widal, service de Psychiatrie d'Adultes, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
38
|
Vorspan F, Mallet L, Corvol JC, Pelissolo A, Lépine JP. Treating addictions with deep brain stimulation is premature but well-controlled clinical trials should be performed. Addiction 2011; 106:1535-6; author reply 1537-8. [PMID: 21749519 DOI: 10.1111/j.1360-0443.2011.03450.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
39
|
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora MEM, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011; 9:90. [PMID: 21791035 PMCID: PMC3163615 DOI: 10.1186/1741-7015-9-90] [Citation(s) in RCA: 1222] [Impact Index Per Article: 94.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Accepted: 07/26/2011] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Major depression is one of the leading causes of disability worldwide, yet epidemiologic data are not available for many countries, particularly low- to middle-income countries. In this paper, we present data on the prevalence, impairment and demographic correlates of depression from 18 high and low- to middle-income countries in the World Mental Health Survey Initiative. METHODS Major depressive episodes (MDE) as defined by the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DMS-IV) were evaluated in face-to-face interviews using the World Health Organization Composite International Diagnostic Interview (CIDI). Data from 18 countries were analyzed in this report (n = 89,037). All countries surveyed representative, population-based samples of adults. RESULTS The average lifetime and 12-month prevalence estimates of DSM-IV MDE were 14.6% and 5.5% in the ten high-income and 11.1% and 5.9% in the eight low- to middle-income countries. The average age of onset ascertained retrospectively was 25.7 in the high-income and 24.0 in low- to middle-income countries. Functional impairment was associated with recency of MDE. The female: male ratio was about 2:1. In high-income countries, younger age was associated with higher 12-month prevalence; by contrast, in several low- to middle-income countries, older age was associated with greater likelihood of MDE. The strongest demographic correlate in high-income countries was being separated from a partner, and in low- to middle-income countries, was being divorced or widowed. CONCLUSIONS MDE is a significant public-health concern across all regions of the world and is strongly linked to social conditions. Future research is needed to investigate the combination of demographic risk factors that are most strongly associated with MDE in the specific countries included in the WMH.
Collapse
Affiliation(s)
- Evelyn Bromet
- Department of Psychiatry, State University of New York at Stony Brook, South Campus, Stony Brook, NY 11794-8790, NY, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
Recent epidemiological surveys conducted in general populations have found that the lifetime prevalence of depression is in the range of 10% to 15%. Mood disorders, as defined by the World Mental Health and the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, have a 12-month prevalence which varies from 3% in Japan to over 9% in the US. A recent American survey found the prevalence of current depression to be 9% and the rate of current major depression to be 3.4%. All studies of depressive disorders have stressed the importance of the mortality and morbidity associated with depression. The mortality risk for suicide in depressed patients is more than 20-fold greater than in the general population. Recent studies have also shown the importance of depression as a risk factor for cardiovascular death. The risk of cardiac mortality after an initial myocardial infarction is greater in patients with depression and related to the severity of the depressive episode. Greater severity of depressive symptoms has been found to be associated with significantly higher risk of all-cause mortality including cardiovascular death and stroke. In addition to mortality, functional impairment and disability associated with depression have been consistently reported. Depression increases the risk of decreased workplace productivity and absenteeism resulting in lowered income or unemployment. Absenteeism and presenteeism (being physically present at work but functioning suboptimally) have been estimated to result in a loss of $36.6 billion per year in the US. Worldwide projections by the World Health Organization for the year 2030 identify unipolar major depression as the leading cause of disease burden. This article is a brief overview of how depression affects the quality of life of the subject and is also a huge burden for both the family of the depressed patient and for society at large.
Collapse
Affiliation(s)
- Jean-Pierre Lépine
- Hôpital Lariboisière Fernand Widal, Assistance Publique Hôpitaux de Paris Unité INSERM 705 CNRS UMR 8206, Université Paris Diderot, Paris, France
| | - Mike Briley
- NeuroBiz Consulting and Communication, Castres, France
| |
Collapse
|
41
|
Rotge JY, Grabot D, Aouizerate B, Pélissolo A, Lépine JP, Tignol J. Childhood history of behavioral inhibition and comorbidity status in 256 adults with social phobia. J Affect Disord 2011; 129:338-41. [PMID: 20797795 DOI: 10.1016/j.jad.2010.07.031] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2010] [Revised: 07/28/2010] [Accepted: 07/28/2010] [Indexed: 11/26/2022]
Abstract
BACKGROUND Behavioral inhibition (BI), a heritable temperament, predisposes one to an increased risk of social phobia. Recent investigations have reported that BI may also be a precursor to anxiety as well as depressive and alcohol-related disorders, which are frequently comorbid with social phobia. In the present study, we explored the relationship between BI and psychiatric disorders in 256 adults with a primary diagnosis of social phobia. METHODS BI severity was retrospectively assessed with the Retrospective Self-Report of Inhibition (RSRI). The severity of social phobia and the presence of comorbid diagnoses were evaluated with the Liebowitz Social Anxiety Scale (LSAS) and the Mini-International Neuropsychiatric Interview, respectively. RESULTS The RSRI score was significantly and positively correlated with both the LSAS score and the occurrence of a major depressive disorder. No significant association was found with other anxiety and substance-related disorders. LIMITATION The assessment of BI was retrospective and self-reported. CONCLUSION A childhood history of BI was associated with an increased risk of depressive comorbidity in social phobia.
Collapse
Affiliation(s)
- Jean-Yves Rotge
- Department of Psychiatry, Charles Perrens Hospital, Bordeaux, France.
| | | | | | | | | | | |
Collapse
|
42
|
Henry C, M'Bailara K, Lépine JP, Lajnef M, Leboyer M. Defining bipolar mood states with quantitative measurement of inhibition/activation and emotional reactivity. J Affect Disord 2010; 127:300-4. [PMID: 20553823 DOI: 10.1016/j.jad.2010.04.028] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2009] [Revised: 04/27/2010] [Accepted: 04/27/2010] [Indexed: 10/19/2022]
Abstract
OBJECTIVES Mood state heterogeneity in bipolar disorder leads to confusion in diagnosis and therapeutic strategies. Recently, the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) showed that two-thirds of bipolar-depressed patients had concomitant manic symptoms, these characteristics being linked to a more severe form of bipolar disorder. Moreover, manic symptoms occurring during bipolar depression are associated with mood switches induced by antidepressant. It is thus important to best characterize mood episodes with mixed features in order to improve our understanding of the etiopathology and to choose the most appropriate treatment. As dimensional approach can better describe phenomena that are distributed continuously without clear boundaries, we used the MATHYS scale, constructed on a dimensional approach. The aim of the study is to determine whether two dimensions (activation/inhibition and emotional reactivity) improve assessment of bipolar states in which both manic and depressive symptoms are associated. METHODS We included 189 bipolar patients and 90 controls. Bipolar patients were distinguished between those with a major depressive episode without manic symptoms, a major depressive episode with manic symptoms, a mixed state and a manic state. The MATHYS scale provides a total score, quantifying an inhibition/activation process, and a score for emotional reactivity (intensity of emotions). RESULTS We demonstrated that there is a continuum ranging from inhibition to activation (respectively from major depressive episodes without manic symptoms to manic states), with a gradual increase in the severity of the activation. Regarding emotional reactivity, results are quiet different since only major depressive episodes without manic symptoms are characterized by emotional hypo-reactivity while major depressive episodes with manic symptoms, manic and mixed states exhibited emotional hyper-reactivity. CONCLUSIONS The MATHYS scale, providing a score for inhibition/activation process and a score for emotional reactivity, is clearly useful to distinguish bipolar depressive episodes without manic symptoms from those with manic symptoms. This last type of depression appears to belong to a broad spectrum of mixed state. To go further we need to explore if these two types of depression are underlined by different mechanisms and what is the most appropriate treatment for each of them.
Collapse
Affiliation(s)
- Chantal Henry
- INSERM, U 995, IMRB, département de Génétique, Créteil, France.
| | | | | | | | | |
Collapse
|
43
|
Kessler RC, McLaughlin KA, Green JG, Gruber MJ, Sampson NA, Zaslavsky AM, Aguilar-Gaxiola S, Alhamzawi AO, Alonso J, Angermeyer M, Benjet C, Bromet E, Chatterji S, de Girolamo G, Demyttenaere K, Fayyad J, Florescu S, Gal G, Gureje O, Haro JM, Hu CY, Karam EG, Kawakami N, Lee S, Lépine JP, Ormel J, Posada-Villa J, Sagar R, Tsang A, Ustün TB, Vassilev S, Viana MC, Williams DR. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry 2010; 197:378-85. [PMID: 21037215 PMCID: PMC2966503 DOI: 10.1192/bjp.bp.110.080499] [Citation(s) in RCA: 1438] [Impact Index Per Article: 102.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Although significant associations of childhood adversities with adult mental disorders are widely documented, most studies focus on single childhood adversities predicting single disorders. AIMS To examine joint associations of 12 childhood adversities with first onset of 20 DSM-IV disorders in World Mental Health (WMH) Surveys in 21 countries. METHOD Nationally or regionally representative surveys of 51 945 adults assessed childhood adversities and lifetime DSM-IV disorders with the WHO Composite International Diagnostic Interview (CIDI). RESULTS Childhood adversities were highly prevalent and interrelated. Childhood adversities associated with maladaptive family functioning (e.g. parental mental illness, child abuse, neglect) were the strongest predictors of disorders. Co-occurring childhood adversities associated with maladaptive family functioning had significant subadditive predictive associations and little specificity across disorders. Childhood adversities account for 29.8% of all disorders across countries. CONCLUSIONS Childhood adversities have strong associations with all classes of disorders at all life-course stages in all groups of WMH countries. Long-term associations imply the existence of as-yet undetermined mediators.
Collapse
|
44
|
|
45
|
Abstract
OBJECTIVES The present publication sets out to evaluate the position of psychopathology in the 21st century and should also serve as a basis for defining the framework for the future tasks of the WFSBP Task Force. METHODS Review of publications on the various approaches of psychopathology in general and of different tasks, theories and tools of psychopathology approaches in particular. RESULTS The main tasks of psychopathology are, to record and describe experiential and behavioral abnormalities in their intersubjective context, to explain their origin from an objective scientific perspective, and to attempt to understand them from the subjective perspective of the patient. In order to provide stable fundaments for the work in clinical and scientific psychiatry all three components are indispensable. CONCLUSIONS The future of psychiatry hence lies in the hands of a type of psychopathology that we will call Integrative Psychopathology. The main tasks of psychopathology can only be pursued in close cooperation with other branches of science interested in studying psychiatric issues. Whereas contemporary psychopathology must lay the foundations for that cooperation, Integrative Psychopathology must be complemented by further advancements in Theoretical Psychopathology, so as to enable conceptual new developments, which can then be fruitful for cooperative research and psychiatric clinical practice.
Collapse
|
46
|
Fullana MA, Vilagut G, Rojas-Farreras S, Mataix-Cols D, de Graaf R, Demyttenaere K, Haro JM, de Girolamo G, Lépine JP, Matschinger H, Alonso J. Obsessive-compulsive symptom dimensions in the general population: results from an epidemiological study in six European countries. J Affect Disord 2010; 124:291-9. [PMID: 20022382 DOI: 10.1016/j.jad.2009.11.020] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2009] [Revised: 11/03/2009] [Accepted: 11/30/2009] [Indexed: 10/20/2022]
Abstract
BACKGROUND The prevalence of obsessive-compulsive symptom dimensions and their sociodemographic and psychopathological correlates at the population level are unknown. METHOD Obsessive-compulsive symptom dimensions and mental disorders were assessed with the Composite International Diagnostic Interview 3.0 in a random subsample (n=2804) of individuals participating in a cross-sectional survey of the adult general population of six European countries. RESULTS The lifetime prevalence of any obsessive-compulsive symptom dimension was 13%. Harm/Checking was the most prevalent dimension (8%) followed by Somatic obsessions (5%) and Symmetry/Ordering (3%). Females were more likely to have symptoms in Contamination/Cleaning (OR=3, 95%CI=1.06-8.51) and Somatic obsessions (OR=1.88, 95%CI=1.05-3.37). All symptom dimensions were associated with an increased risk of most mental (but not physical) disorders. There were some differences in prevalence between countries. LIMITATIONS The interference associated with each symptom dimension could not be assessed. Few direct data are available on the validity of the CIDI to assess obsessive-compulsive symptom dimensions. CONCLUSIONS Obsessive-compulsive symptom dimensions are relatively frequent in the general population. Their sociodemographic and psychopathological correlates may be slightly different in clinical and community samples. They are associated with an increased risk of most mental disorders.
Collapse
Affiliation(s)
- M A Fullana
- Anxiety Unit, IAPS, Hospital del Mar and Department of Psychiatry, Autonomous University of Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
de Graaf R, Radovanovic M, van Laar M, Fairman B, Degenhardt L, Aguilar-Gaxiola S, Bruffaerts R, de Girolamo G, Fayyad J, Gureje O, Haro JM, Huang Y, Kostychenko S, Lépine JP, Matschinger H, Mora MEM, Neumark Y, Ormel J, Posada-Villa J, Stein DJ, Tachimori H, Wells JE, Anthony JC. Early cannabis use and estimated risk of later onset of depression spells: Epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. Am J Epidemiol 2010; 172:149-59. [PMID: 20534820 DOI: 10.1093/aje/kwq096] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Early-onset cannabis use is widespread in many countries and might cause later onset of depression. Sound epidemiologic data across countries are missing. The authors estimated the suspected causal association that links early-onset (age <17 years) cannabis use with later-onset (age > or =17 years) risk of a depression spell, using data on 85,088 subjects from 17 countries participating in the population-based World Health Organization World Mental Health Survey Initiative (2001-2005). In all surveys, multistage household probability samples were evaluated with a fully structured diagnostic interview for assessment of psychiatric conditions. The association between early-onset cannabis use and later risk of a depression spell was studied using conditional logistic regression with local area matching of cases and controls, controlling for sex, age, tobacco use, and other mental health problems. The overall association was modest (controlled for sex and age, risk ratio = 1.5, 95% confidence interval: 1.4, 1.7), was statistically robust in 5 countries, and showed no sex difference. The association did not change appreciably with statistical adjustment for mental health problems, except for childhood conduct problems, which reduced the association to nonsignificance. This study did not allow differentiation of levels of cannabis use; this issue deserves consideration in future research.
Collapse
Affiliation(s)
- Ron de Graaf
- Department of Epidemiology, Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, Alonso J, Angermeyer M, Anthony JC, Bruffaerts R, de Girolamo G, de Graaf R, Gureje O, Karam AN, Kostyuchenko S, Lee S, Lépine JP, Levinson D, Nakamura Y, Posada-Villa J, Stein D, Wells JE, Kessler RC. Evaluating the drug use "gateway" theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend 2010; 108:84-97. [PMID: 20060657 PMCID: PMC2835832 DOI: 10.1016/j.drugalcdep.2009.12.001] [Citation(s) in RCA: 169] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2008] [Revised: 12/01/2009] [Accepted: 12/02/2009] [Indexed: 10/20/2022]
Abstract
BACKGROUND It is unclear whether the normative sequence of drug use initiation, beginning with tobacco and alcohol, progressing to cannabis and then other illicit drugs, is due to causal effects of specific earlier drug use promoting progression, or to influences of other variables such as drug availability and attitudes. One way to investigate this is to see whether risk of later drug use in the sequence, conditional on use of drugs earlier in the sequence, changes according to time-space variation in use prevalence. We compared patterns and order of initiation of alcohol, tobacco, cannabis, and other illicit drug use across 17 countries with a wide range of drug use prevalence. METHOD Analyses used data from World Health Organization (WHO) World Mental Health (WMH) Surveys, a series of parallel community epidemiological surveys using the same instruments and field procedures carried out in 17 countries throughout the world. RESULTS Initiation of "gateway" substances (i.e. alcohol, tobacco and cannabis) was differentially associated with subsequent onset of other illicit drug use based on background prevalence of gateway substance use. Cross-country differences in substance use prevalence also corresponded to differences in the likelihood of individuals reporting a non-normative sequence of substance initiation. CONCLUSION These results suggest the "gateway" pattern at least partially reflects unmeasured common causes rather than causal effects of specific drugs on subsequent use of others. This implies that successful efforts to prevent use of specific "gateway" drugs may not in themselves lead to major reductions in the use of later drugs.
Collapse
Affiliation(s)
- Louisa Degenhardt
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, Zohar J, Hollander E, Kasper S, Möller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2009; 9:248-312. [PMID: 18949648 DOI: 10.1080/15622970802465807] [Citation(s) in RCA: 420] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.
Collapse
Affiliation(s)
- Borwin Bandelow
- Department of Psychiatry and Psychotherapy, University of Gottingen, Gottingen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Lara C, Fayyad J, de Graaf R, Kessler RC, Aguilar-Gaxiola S, Angermeyer M, Demytteneare K, de Girolamo G, Haro JM, Jin R, Karam EG, Lépine JP, Mora MEM, Ormel J, Posada-Villa J, Sampson N. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry 2009; 65:46-54. [PMID: 19006789 PMCID: PMC2629074 DOI: 10.1016/j.biopsych.2008.10.005] [Citation(s) in RCA: 270] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2008] [Revised: 09/23/2008] [Accepted: 10/02/2008] [Indexed: 11/26/2022]
Abstract
BACKGROUND Although it is known that childhood attention-deficit/hyperactivity disorder (ADHD) often persists into adulthood, childhood predictors of this persistence have not been widely studied. METHODS Childhood history of ADHD and adult ADHD were assessed in 10 countries in the World Health Organization World Mental Health Surveys. Logistic regression analysis was used to study associations of retrospectively reported childhood risk factors with adult persistence among the 629 adult respondents with childhood ADHD. Risk factors included age; sex; childhood ADHD symptom profiles, severity, and treatment; comorbid child/adolescent DSM-IV disorders; childhood family adversities; and child/adolescent exposure to traumatic events. RESULTS An average of 50% of children with ADHD (range: 32.8%-84.1% across countries) continued to meet DSM-IV criteria for ADHD as adults. Persistence was strongly related to childhood ADHD symptom profile (highest persistence associated with the attentional plus impulsive-hyperactive type, odds ratio [OR]=12.4, compared with the lowest associated with the impulsive-hyperactive type), symptom severity (OR=2.0), comorbid major depressive disorder (MDD; OR=2.2), high comorbidity (>or=3 child/adolescent disorders in addition to ADHD; OR=1.7), paternal (but not maternal) anxiety mood disorder (OR=2.4), and parental antisocial personality disorder (OR=2.2). A multivariate risk profile of these variables significantly predicts persistence of ADHD into adulthood (area under the receiving operator characteristic curve=.76). CONCLUSIONS A substantial proportion of children with ADHD continue to meet full criteria for ADHD as adults. A multivariate risk index comprising variables that can be assessed in adolescence predicts persistence with good accuracy.
Collapse
Affiliation(s)
- Carmen Lara
- Autonomous University of Puebla, Puebla, Mexico
| | - John Fayyad
- Institute for Development, Research, Advocacy, and Applied Care (IDRAAC), St. George Hospital University Medical Center, Beirut, Lebanon
| | - Ron de Graaf
- Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands
| | - Ronald C. Kessler
- Health Care Policy, Harvard Medical School, Boston, Massachusetts, United States
| | - Sergio Aguilar-Gaxiola
- Center for reducing Health Disparities, University of California, Sacramento, California, United States
| | | | | | | | | | - Robert Jin
- Health Care Policy, Harvard Medical School, Boston, Massachusetts, United States
| | - Elie G. Karam
- Institute for Development, Research, Advocacy, and Applied Care (IDRAAC), St. George Hospital University Medical Center, Beirut, Lebanon
| | | | - Maria Elena Medina Mora
- Division of Epidemiological and Social Research, Mexican Institute of Psychiatry, Mexico City, Mexico
| | - Johan Ormel
- Department of Psychiatry & Department of Epidemiology and Bioinformatics, University Medical Center Groningen; Graduate School of Behavioural and Cognitive Neurosciences & Graduate School for Experimental Psychopathology, University of Groningen, the Netherlands
| | - José Posada-Villa
- Ministry of Social Protection, Colegio Mayor de Cundinamarca University, Bogota, Colombia
| | - Nancy Sampson
- Health Care Policy, Harvard Medical School, Boston, Massachusetts, United States
| |
Collapse
|